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striatum, possibly contributing to striatal vulnerability in HD, and that while RBM3 enhances components of
the mTORC1 pathway, it is insufficient to rescue HD phenotypes.
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ABSTRACT
INVESTIGATING THE DYSREGULATION AND THERAPEUTIC POTENTIAL OF
NEUROPROTECTIVE STRESS RESPONSE PROTEINS IN HUNTINGTON’S DISEASE
Julianne M. Rieders
Beverly L. Davidson, Ph.D.
Huntington’s disease (HD) is a fatal, genetic neurodegenerative disease that shares many
features with other common neurological disorders, including early synapse loss. In both human
HD brain and murine models, apoptotic pathways are dysregulated and mammalian target of
rapamycin complex 1 (mTORC1) activity is reduced. These pathways are of particular interest
because they regulate cell survival and metabolism, and enhancing mTORC1 is protective in HD
models. RNA binding motif protein 3 (RBM3) is a stress response protein that promotes synaptic
plasticity and cell survival, and is dysregulated in Alzheimer, prion and HD models. Hippocampal
overexpression of RBM3 in Alzheimer and prion murine models is neuroprotective and in the
setting of prion disease is mediated by reticulon 3 (RTN3), a downstream target of RBM3. Here, I
show that RBM3 and RTN3 are dysregulated in in vitro and in vivo models of HD. I find that
overexpressing RBM3 isoform 1 or RTN3 in the striatum of HD mice does not rescue disease
phenotypes. I also find that overexpressing RBM3 isoform 1 or 2 in the striatum does not increase
RTN3 levels as expected. Further, I provide evidence that cold stress and RBM3 overexpression
enhances components of the mTORC1 pathway in vitro and in vivo. My combined work indicates
that the RBM3-RTN3 axis may function differently in the striatum, possibly contributing to striatal
vulnerability in HD, and that while RBM3 enhances components of the mTORC1 pathway, it is
insufficient to rescue HD phenotypes.
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CHAPTER 1
Introduction

Huntington’s Disease
Overview
Huntington’s disease (HD) is a devastating neurodegenerative disease characterized by cognitive
decline, progressive motor dysfunction, and psychiatric disorder. HD has a prevalence of 10 per
100,000 individuals, a mean onset at the age of 40, and death occurring 10-20 years after
diagnosis1. HD results from an expansion of CAG repeats in exon 1 of the huntingtin gene, which
leads to expression of aberrant huntingtin (HTT) protein with an expanded polyglutamine (polyQ)
tract2. Repeat lengths of 16-20 are typical, while repeats greater than 35 are disease-causing and
repeats of 41 or greater are fully penetrant3. Age of onset is largely predicted by repeat length,
with longer repeat lengths corresponding to an earlier age of onset4.
Normal huntingtin protein (HTT) is ubiquitously expressed and necessary for development, with
proposed roles in transcription, vesicle transport, and RNA trafficking5 . Within neurons, mutant
HTT (mHTT) forms characteristic intranuclear and cytoplasmic aggregates6,7. Many proteins,
such as transcription factors8,9, are sequestered by mHTT aggregates, causing a complex lossof-function phenotype and further compounding the cell’s inability to process misfolded proteins.
mHTT is also cleaved to form toxic fragments that can exist in several different pathologic
conformations10. The expression of mHTT induces a cascade of cellular changes, leading to
neuronal dysfunction and death. mHTT causes widespread transcriptional changes, leading to
altered mRNA and microRNA (miRNA) profiles in HD patients and animal models11–15. Despite
mHTT’s ubiquitous expression and broad pathogenic effects, degeneration progresses selectively
throughout brain regions with early and prominent degeneration occurring in the striatum followed
by the cortex16.
Motor symptoms include chorea, dystonia, limb rigidity, bradykinesia, and incoordination. Notably,
aspiration pneumonia due to the loss of swallowing coordination is the major cause of death in
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HD patients17. Common psychiatric symptoms include depression and anxiety, and HD patients
are at greater risk of suicide18. Peripheral symptoms, such as weight loss and increased risk of
heart failure19, also manifest in HD patients, with heart disease being the second leading cause of
death20–22. Despite rigorous study and numerous clinical trials, there is currently no diseasemodifying treatment for HD. However, anti-sense oligonucleotide and adeno-associated virus
(AAV) mediated knock-down of HTT mRNA has proven safe and efficacious in preclinical models
and are progressing to the clinic23–26.

Common HD models
In vitro
In vitro models allow us to study the effect of mHTT expression on various cellular processes in a
highly controlled setting. The STHdhQ7/Q111 striatal-like cell model of HD was established from fulllength wild type (WT, 7 polyQ stretch) and mutant (HD, 111 polyQ stretch) HTT knock-in murine
striatal precursor cells. E14 striatal precursor cells were immortalized using the tsA58 SV40 large
T antigen27. This model recapitulates many characteristics of HD pathogenesis, including altered
metabolism, mitochondrial dysfunction, and dysregulation of apoptotic pathways27–29. I will refer to
this model as Q7 and Q111 cells, respectively, throughout this thesis.
In vivo
Fragment models
Given that mHTT is cleaved to form various toxic fragment species, multiple murine models have
been developed that express N-terminal truncations of mHTT. The R6/2 mouse was the first
transgenic HD mouse model, expressing the HTT exon 1 N-terminal fragment with approximately
150 CAG repeats driven by ~1kb of the human HTT promoter. This model recapitulates many HD
phenotypes, such as neuronal mHTT inclusions, striatal atrophy, and progressive motor deficits30.
However, this model’s extremely rapid progression, with death normally occurring at 10-13
weeks, can pose experimental challenges to assessing therapeutic interventions. Another
fragment model is the N171-82Q mouse, which expresses the truncated 171 amino acid N-
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terminus of human HTT containing an 82 polyQ-stretch driven by the mouse prion protein
promoter31. N171-82Q mice recapitulate many aspects of HD, including reduced body weight with
failure to gain weight starting at 8 weeks, metabolic dysfunction at 10 weeks, striatal atrophy at 11
weeks, overt motor decline at 12 weeks, and a shortened lifespan of 24 weeks31. This
progression, while still rapid, allows for a longer window of intervention amenable to preclinical
studies.
Full length models
Several murine models have been developed to study the effect of full length human mHTT
expression. A yeast artificial chromosome (YAC) model encompassing the entire human HTT
gene with a 128 CAG repeat (YAC128) shows progressive motor deficits starting at 3 months
corresponding with striatal and cortical degeneration32 These mice also display mHTT
aggregation, mitochondrial dysfunction, and dysregulation of apoptotic pathways33. A bacterial
artificial chromosome model (BACHD) containing the entire human HTT locus that expresses the
full length human HTT gene driven by the human promoter with 97 mixed CAA/CAG repeats
recapitulates many of the same phenotypes. The onset of symptoms in these mice occurs at 2
months but are robust at 6 months, and include sparse mHTT inclusions in the cortex and
striatum, reduced cortical and striatal volume, and motor deficits34. Both YAC128 and BACHD
mice have a normal lifespan, and unlike HD patients have an increased body weight over time.
Because these models express full length human mHTT, they have been useful in developing
RNA interference (RNAi) and gene editing therapies that can be more readily translated to the
clinic.
Knock-in models
Knock-in models, in which CAG repeat expansions are directly introduced into the endogenous
mouse Htt locus, better recapitulate the genetic context and gene expression levels compared to
the transgenic models. These mice typically have a normal life span and a relatively mild
phenotype. The HdhQIII knock-in mice express chimeric HTT containing human exon 1 with a
111 CAG repeat expansion, and have neuronal inclusions by 4.5 months and gait abnormalities
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by 24 months35,36. This line is notable as the source of the immortalized Q7/Q111 cell model
described above. A similar chimeric line called zQ175 was derived from the spontaneous
expansion of an established knock-in model with 140 CAG repeats37. This model, which
expresses 190 CAG repeats, shows weight loss and a progressive motor phenotype starting
around 7 months in heterozygous mice38, as well as decreased cortical and striatal volumes at 12
months39.

In contrast to these chimeric knock-in models, an allelic series of knock-in mice

expressing mouse HTT with a range of repeats from 50 to 365 without any human genetic
elements shows striatal inclusions at 7 months and motor deficits around 18 months40,41. While
these models take longer to develop robust HD phenotypes, they allow for more in-depth studies
of pre-symptomatic disease progression and may better reflect underlying disease mechanisms.

Mammalian target of rapamycin signaling pathway
The mammalian target of rapamycin (mTOR) signaling pathway is a primary regulator of cell
metabolism, growth, proliferation, and survival in response to growth factors and nutrients.
Relevant components of this pathway are summarized in figure 1.1. mTOR is a 289 kDa
serine/threonine kinase that forms the catalytic subunit of mTOR complex 1 (mTORC1). When
activated, mTORC1 promotes protein synthesis by increasing cap-dependent translocation,
translational elongation, and mRNA and ribosome biogenesis through phosphorylation of p70
ribosomal S6 kinase 1 (S6K1) and eukaryotic initiation factor 4E (eIF4E) binding protein 1
(4EBP1). S6K1 regulates multiple downstream targets, including the ribosomal protein S6, which
promotes the translation of ribosomal proteins. Phosphorylation of 4EBP1 inhibits its binding to
eIF4E thereby enhancing cap-dependent translation. Phospho-S6 (pS6) and phospho-4EBP1
(p4EBP1) are therefore commonly used markers of mTORC1 activity. mTORC1 regulates lipid
and cholesterol synthesis, which is necessary for cell growth and proliferation, through activation
of the transcription factors sterol regulatory element binding protein 1 (SREBP1) and peroxisome
proliferator-activated receptor-g (PPARg). Mitochondrial biogenesis and metabolism are also
strongly influenced by mTORC1 activation through the transcriptional cofactor PPARg coactivator
1 (PGC1-α)42,43.
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Growth factors, ATP levels, oxygen levels, amino acids, and some forms of stress all influence
mTORC1 signaling. Here, I will focus on the relevant components of the phosphatidylinositol-3kinase (PI3K)/AKT/mTOR axis, which responds to growth factors and hormones such as insulin.
PI3K activation leads to phosphorylation of AKT, which in turn represses the tuberous sclerosis
complex (TSC), a GTPase-activating protein comprised of TSC1 and TSC2. TSC1/2 inhibits the
direct activator of mTORC1, the GTPase Ras homologue enriched in brain (Rheb); thus, AKT
mediated inhibition of TSC1/2 activates mTORC1 through Rheb. AKT also inhibits glycogen
synthase kinase 3 (GSK3), a component of the Wnt signaling pathway that promotes TSC1/2
activity44,45. Phospho-AKT levels (pAKT) are therefore commonly assessed as an upstream
marker of mTORC1 activity. It is important to note that these processes are complex and include
many more factors than are noted here. Many of these proteins are involved in feedback loops
and interact with other arms of the mTOR signaling pathway. For example, activated S6K1
inhibits the PI3K/AKT/mTORC1 pathway upstream of PI3K creating a negative feedback loop46. It
is essential to consider these dynamics when interpreting experimental data, which is often a
single snapshot of this process.

Restoring mTORC1 activity is beneficial in Huntington’s Disease
mTORC1 activity is reduced in brains of HD patients and in mouse models28. In addition to
observed metabolic deficits in HD patients47,48 mitochondrial dysfunction is evident from HD
human and animal studies29,49–52. Extensive work in murine models have demonstrated that
PGC1-α is directly suppressed by mHTT29,51,53. In addition, overexpression of PGC1-α promotes
clearance of mHTT aggregates54 and reverses motor phenotypes in HD mice29. Enhancing
mTORC1 activity in the striatum of N171-82Q mice by overexpression of the mTORC1 activator
Rheb increases PGC1-α expression and corrects multiple clinical phenotypes including
mitochondrial dysfunction. Further, in this model restoring the mTORC1 activator Ras homologue
enriched in striatum (Rhes), which is reduced in HD patient brain and in presymptomatic N17182Q mice, similarly increased PGC1-α levels and improved motor deficits28. In the periphery,
dysregulation of cardiac mTORC1 activity was recently shown to underlie the maladaptive cardiac
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stress response phenotype observed in N171-82Q mice. In late-stage N171-82Q heart tissue,
analysis of membrane and cytoplasmic fractions revealed Rheb is significantly reduced in the
membrane fraction and increased in the cytoplasmic fraction, indicating mislocalization.
Overexpression of Rheb in heart tissue significantly increased survival of N171-82Q mice in
response to cardiac stress and corrected several morphological heart phenotypes55.
In the central nervous system, augmentation of mTORC1 activity promotes axon regeneration
and synaptic plasticity56–58. Altered synaptic plasticity and neurotransmission are detected early in
HD patients and animal models59,60. Medium spiny neurons (MSNs) represent 90% of neurons in
the striatum and are prominently affected in HD. Analysis of MSNs in HD patient brain reveals
abnormal morphology in dendritic spines, which are the dynamic projections essential for synaptic
transmission and plasticity. Presymptomatic dysfunction in synaptic plasticity is apparent in
multiple HD murine models32,61–65. In addition, several neurotransmitter systems are abnormal in
HD, including the dopamine signaling pathway64–67. Multiple components of the dopamine
signaling pathway are deficient in HD patients and murine models, including the dopamine- and
cAMP-regulated phosphoprotein Mr 32 kDa (DARPP-32) present in striatal MSNs, which is
commonly used as a marker of disease progression28,64,65. Promotion of mTORC1 activity in
N171-82Q mice rescues DARPP-32 levels and reverses abnormalities in striatal atrophy and
MSN area28. The broad beneficial effects of enhancing mTORC1 activity in HD motivate the
search for novel mTORC1 regulators.

Cold inducible RNA binding motif protein 3
RBM3 is neuroprotective
RNA binding motif protein 3 (RBM3) was first identified as a cold induced protein in hibernating
animals. During hibernation body temperature drops and metabolism slows as a means of
conserving energy during periods of food insufficiency. Protein synthesis is globally repressed,
however the expression of a small group of cold induced proteins, including RBM3, increases68,69.
RBM3 is optimally induced by a moderate drop in temperature of around 5°C70, which is
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approximately the temperature change in large hibernating mammals such as bears (3-5°C),
while many small mammals experience much greater drops in body temperature during deep
hibernation (>30°C)71. Intriguingly, in humans clinically-induced hypothermia, in which body
temperature is dropped to 32-34°C, is neuroprotective following neonatal hypoxic-ischemic
encephalopathy and adult acute brain injury72. The reduction in metabolism alone does not
account for the beneficial effect of cooling, and animal studies indicate that RBM3 mediates
cooling induced neuroprotection73,74. Remarkably, during mammalian hibernation synaptic
contacts are dismantled and reformed upon warming75. Moreover, loss of synaptic contacts is a
common early feature of neurodegenerative diseases76–78. Hence RBM3 has become of interest
as a broadly neuroprotective protein.
RBM3 is highly expressed throughout the developing brain and in proliferative regions in the adult
brain73. RBM3 is present in the nucleus, cytoplasm, and in heterogeneous granules containing
mRNA and miRNA in neuronal dendrites79,80. During cellular stress such as hypothermia and
hypoxia, RBM3 expression is induced in the brain, where it augments synaptogenesis and global
protein translation73,79–82. In the Alzheimer’s Disease (AD) 5XFAD murine model and in mice
infected with Rocky Mountain Laboratory (RML) prions, synapse regeneration is impaired
following induction of hypothermia due to a failure to induce RBM3. Further, overexpression of
RBM3 reverses the impairment in synaptogenesis in 5XFAD mice, and prevents behavioral
deficits, neuronal loss, and prolongs survival in RML prion mice74.
Protein structure
is a highly conserved RNA-binding protein that is a member of a small subset of cold-induced
stress response proteins. RBM3 is a 17 kDa protein with an N-terminal RNA-binding domain
featuring a conserved RNA-recognition motif (RRM) with two ribonucleoprotein domains, RNP1
and RNP2. The C-terminal of RBM3 contains an arginine-glycine rich (RGG) domain. This
subfamily of glycine-rich proteins containing both an RRM and RGG domain are highly conserved
at both the sequence and functional levels, with conserved function in responding to cold stress
and regulating circadian rhythm even present in plants83. Humans have a single RBM3 isoform
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(hRBM3), while mice have two isoforms (mRBM3iso1 and mRBM3iso2). Human and mouse
RBM3 share 94% identity, and mRBM3iso1 and mRBM3iso2 differ only by the addition of a single
arginine residue in RGG domain of isoform 1. At this region, hRBM3 retains the additional
arginine residue, and therefore is more similar to mRBM3iso1. While in vitro overexpression
studies suggest that mRBM3iso1 is more highly enriched in the nucleus and mRBM3iso2 is more
highly enriched in the cytoplasm80, there are no reported differences in function between the two
isoforms.
Mechanism
RBM3 regulates post-transcriptional gene expression by mediating RNA stability, alternative
polyadenylation84, alternative splicing85, and miRNA biogenesis86. Consistent with these roles,
Photoactivatable-Ribonucleoside-Enhanced

(PAR)-CLIP

performed

on

mouse

embryonic

fibroblasts constitutively expressing FLAG-tagged RBM3 revealed that RBM3 binding sites are
distributed throughout the coding sequence, intron, and 3’UTR of genes84. This study identified
5,300 RBM3 target genes, indicating RBM3 likely acts on multiple pathways which may underlie
its broadly neuroprotective nature. Alterations in RBM3 strongly influence miRNA biogenesis,
including miRNAs involved in proliferation, synaptic plasticity, and apoptosis79,86. The mechanism
of RBM3 mediated neuroprotection is slowly being elucidated, as summarized in figure 1.2.
RBM3 increases global protein synthesis in part through direct interaction with the large
ribosomal subunit 60S, leading to increased ribosome association79. Boosting total protein
expression may help to maintain baseline protein expression when proteostasis is severely
impacted.
In the setting of prion disease, reticulon 3 (RTN3), a resident endoplasmic reticulum (ER) protein
important in stabilizing curved membranes, primarily mediates RBM3’s neuroprotective effect.
RBM3 increases RTN3 translation by binding to the 5’UTR and promoting initiation87. RTN3 likely
reduces ER stress, however the exact beneficial effect of RTN3 is unclear. In organotypic
hippocampal slice cultures treatment with the ER stress inducer thapsigargin led to
hyperactivation of the PRKR-like ER kinase (PERK)/ eukaryotic translation initiation factor 2a
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(eiF2a)/ CCAAT enhancer-binding protein homologous protein (CHOP) ER stress pathway in
RBM3 knock-out mice. In wild type (WT) slice cultures treated with thapsigargin pre-treatment
with moderate hypothermia reduced PERK/eiF2a/CHOP signaling. The authors determined that
RBM3 directly acts on PERK in a manner dependent on nuclear factors associated with dsRNA
family

NF90

protein,

likely

as

a

ribonucleoprotein

complex,

ultimately

reducing

PERK/eiF2a/CHOP mediated apoptosis83. Given that RBM3 has over 5,000 RNA targets and is
neuroprotective in multiple disease and stress contexts, it likely acts through multiple synergistic
pathways towards promoting cell survival. Significantly more work needs to be done to elucidate
the RBM3 functions that contribute to neuroprotection

A possible role for RBM3 in Huntington’s Disease
RBM3 dysregulation has also been implicated in the pathogenic cascade in HD88. RBM3 is
rapidly downregulated in an inducible cell model of HD and RBM3 overexpression reduces polyQmediated cell death in vitro88. This raises the possibility that RBM3 dysregulation has a direct role
in HD pathogenesis. Intriguingly, RBM3 overexpression increases p4EBP1 levels in neuronal cell
lines80. and both RBM3 and mTORC1 mediate global protein synthesis and synaptogenesis,
suggesting that they are mechanistically connected. Taken together, experimental evidence
indicates that deficits in RBM3 induction play a common role in neurodegenerative diseases and
that elevation of RBM3 is broadly neuroprotective, possibly through enhancing mTORC1 activity
in HD.

Goals of this thesis
In this thesis I investigate RBM3 dysregulation in HD in vitro and in vivo models, and in HD
patient samples. Previous groups have demonstrated deficits in RBM3 induction by cold stress
after the onset of neurodegenerative disease in murine models, suggesting RBM3 dysregulation
is secondary to disease pathology. Evidence that mHTT rapidly represses RBM3 expression
suggests RBM3 dysregulation may be an upstream event in the pathological cascade in HD. I
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aim to assess RBM3 at baseline and under stress in the setting of mHTT to better clarify its
dysregulation and potential as a therapeutic target in HD.
To probe the connection between RBM3 and the mTORC1 pathway I investigate the effect of
cold stress on the mTORC1 pathway in vitro. Further, I assess the effect of RBM3 overexpression
on HD disease phenotypes in vivo, using behavioral and molecular markers of disease. To do so
I directly overexpressed RBM3 in the striatum of HD mice and measured weight gain, motor
performance, DARPP-32 levels, mTORC1 activity, and RTN3 levels. RTN3 was shown to be the
mediator of RBM3’s protective effects in a prion disease mouse model. To determine if RTN3 is
also a relevant therapeutic target in HD we similarly overexpressed RTN3 and measured disease
outcomes. In addition, we investigated the RBM3-RTN3 axis in different cell types to further
elucidate the importance of RTN3 in the striatum.
Finally, in mice there are two isoforms of RBM3 differing by only a single arginine residue. While
there are differences in their cellular distribution, there are no known differences in their function.
Previously mRBM3iso2 overexpression was shown to be beneficial in AD and prion disease
models, but overexpression of mRBM3iso1 has not been explored in vivo. We overexpressed
mRBM3iso1 or iso2 in the striatum of HD and WT mice to compare the effects on RTN3
expression and mTORC1 activation.
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Figures

Figure 1.1 Relevant components of mTORC1 pathway
The PI3K/AKT/mTORC1 pathway is activated in response to growth factors like insulin and IGF.
When activated, PI3K activates AKT, which represses TSC1/2. TSC1/2 deactivates the direct
activator of mTORC1, Rheb. AKT also inhibits the TSC1/2 activator GSK3, reducing TSC1/2
activity indirectly. When mTORC1 is activated by Rheb, it phosphorylates S6K1 and 4EBP1.
Activated S6K1 phosphorylates S6, leading to increased translation of ribosomal proteins.
Activated S6K1 also represses activation of PI3K, creating a negative feedback loop.
Phosphorylation of 4EBP1 prevents it from binding and repressing eIF4E, thereby
phosphorylation of 4EBP1 increases cap-dependent translation.
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Figure 1.2 Summary of RBM3 neuroprotective mechanisms
RBM3 increases RTN3, a resident ER protein important for stabilizing curved membranes,
through binding the RTN3 5’UTR and enhancing translation. Increased RTN3 is neuroprotective
in prion-infected mice, possibly through reducing ER stress and indirectly increasing protein
synthesis (1). RBM3, as part of a ribonucleoprotein complex with NF90, directly reduces
maladaptive ER stress by repressing PERK activation, thereby reducing the PERK/eIF2a/CHOP
ER stress pathway, which induces apoptosis and represses translation (2). RBM3 directly
interacts with the large ribosomal subunit 60S through RNA-independent binding, increasing 80S
monosome and polysome association leading to increased translation (3). RBM3 negatively
regulates the translational repressor 4EBP1 by increasing its phosphorylation through unknown
mechanisms (4).
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CHAPTER 2
RBM3 is dysregulated in Huntington’s Disease

Introduction
Due to the widespread cellular dysfunction in HD, distinguishing between disease causing,
compensatory, and irrelevant gene expression changes has been a major challenge. Utilizing a
doxycycline inducible PC12 HD model expressing eGFP fused to HTT exon 1 with 23 or 74 polyQ
repeats, Kita et al. assessed gene expression changes at 0, 5, 10, and 18 hours after induction of
mHTT expression. This time window, before HD-74Q cells show mitochondrial dysfunction and
increased cell death, was chosen to capture early gene expression changes and exclude
secondary nonspecific changes common to generally unhealthy cells. RBM3 was identified as a
part of the most rapidly downregulated gene cluster, along with various transcription factors,
ribosomal proteins, and lipid-binding proteins1. mHTT can directly reduce gene expression by
binding the promoter region of repressed genes and interfering with transcription factors2,3. The
rapid repression of RBM3 suggests its dysregulation occurs early in HD, possibly due to direct
repression by mHTT. This is in contrast to recent findings that RBM3 induction, but not baseline
expression, is dysregulated in an Alzheimer’s disease (AD) and prion disease mouse model4,
suggesting different mechanisms behind RBM3 dysregulation. To test my hypothesis that RBM3
is dysregulated in HD, I investigated RBM3 expression in postmortem HD patient brain, as well as
in in vitro and in vivo models of HD.

Results
RBM3 mRNA levels trend lower in HD patient brain
We previously generated an mRNA sequencing data set in which mRNA sequencing was
performed on RNA isolated from the Brodmann Area 4 (BA4) motor cortex of 7 HD patients and 7
control patients5. The cortex is commonly used in HD studies because it undergoes gene
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expression changes similar to the striatum with relatively less neuronal cell loss6. In preliminary
RNAseq data of HD brains, I observed a correlation between decreased RBM3 mRNA levels and
diseased state compared to controls as measured in Fragments Per Kilobase of transcript per
Million mapped reads (data not shown). We were able to obtain additional RNA samples for a
total of 14 HD and 15 controls and validated our findings by RT-qPCR. I found that RBM3 mRNA
levels trend lower in HD cortex compared to controls (figure 2.1). It is evident from the range of
values that there is a much greater spread in RBM3 mRNA levels in HD patient cortex compared
to a relatively tight range in control cortex. While the difference in RBM3 levels does not reach
significance, the difference in variance between the two groups is significant.
Given that RBM3 is a stress response protein, I wondered if a specific stress-related variable
could account for the greater variance in RBM3 in HD brains. For all samples I considered patient
age, sex, and Vonsattel grade, a 0-4 measure of disease progression in postmortem HD brain
based on macroscopic and microscopic neuropathology7, but found these variables do not
explain the variance in RBM3 levels. We had information on CAG repeat length for a subset of 7
patients, making it difficult to draw any conclusions, but CAG repeat length does not seem to be a
likely explanation. This data is summarized in Table 1.1. It is possible that other unknown factors
such as cause of death account for these differences, as hypoxia, which induces RBM38, is
common leading up to and during brain death. Nonetheless, the significantly increased variability
in RBM3 levels supports the hypothesis that RBM3 expression is dysregulated in HD.
Knock-down of mHTT increases Rbm3
mHTT represses transcription by occupying the promoter of repressed genes and interfering with
transcriptional activation factors2. mHTT repression of PGC1-α involves CRE-dependent
transcription, which is dependent on the CRE-site in the PGC1-α promoter3. Intriguingly, the
RBM3 promoter also contains two CRE consensus motifs suggesting a similar mechanism of
repression mediated directly by mHTT. To determine the effects of knocking down mHTT on
Rbm3 expression, I obtained cDNA samples from BACHD and WT mice treated with an artificial
miRNA (miHDS1v6a) targeting total HTT via AAV delivery to the striatum9. I found that ~50%
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reduction of HTT significantly increases Rbm3 mRNA levels in 6-month-old BACHD mice, but not
in WT mice (figure 2.2). I did not observe differences in Rbm3 mRNA between mock treated WT
and BACHD mice. The finding that knockdown of mHTT but not WT HTT affects Rbm3
expression supports my hypothesis that mHTT directly or indirectly represses Rbm3 expression.
Baseline and induced Rbm3 expression is blunted in vitro
To assess RBM3 in a more controlled setting, I measured basal (37°C) and cold stress (33°C)
induced Rbm3 mRNA levels in murine striatal-like HD cells expressing expanded (Q111) and
normal (Q7) HTT. I found that baseline levels of Rbm3 mRNA are significantly reduced in Q111
cells compared to Q7 cells. In addition, induction of RBM3 by moderate hypothermia (33°C) for
24 hours (h) is insufficient to overcome the differences in Rbm3 expression. Rbm3 expression is
significantly reduced in cold stressed Q111 cells compared to cold stressed Q7 cells (figure
2.3A). Further, the change in Rbm3 expression (Rbm3 mRNA at 33°C/Rbm3 mRNA at 37°C) is
also significantly reduced in Q111 cells, indicating both a baseline deficit and blunted RBM3
stress response in the setting of mutant huntingtin expression (figure 2.3B).
In contrast, RBM3 protein levels generally do not differ between Q7 and Q111 cells at baseline or
following cold stress (figure 2.3C). Notably, in two independent experiments at low passage I
observed significant differences in RBM3 levels at baseline or upon cold stress, suggesting stress
related to the thawing or passaging process differentially affects these cell lines. It is possible that
under these conditions the Q111 cells were no longer able to “keep up” and differences in RBM3
levels became evident. Conversely, it is also possible that the process of passaging differentially
stresses the cells, so at early passages I was able to capture the deficit at baseline in Q111 cells,
whereas at later passages I was capturing the Q7 cells at baseline, but the Q111 cells under
higher stress conditions resulting in similar levels of RBM3. These observations point to the
difficulty in studying stress response proteins, particularly those that are robustly induced by small
environmental fluctuations such as RBM3. Given the challenge in identifying the precise
conditions under which these deficits could be observed I did not further characterize these
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dynamics. Nevertheless, the reduction in Rbm3 mRNA but not protein under most conditions
indicates increased RBM3 translation or increased protein stability in the setting of mHTT.
RBM3 protein is reduced in the cortex of N171-82Q mice
To validate these findings in vivo I next assessed RBM3 in the N171-82Q HD murine model. At
18 weeks, which is late stage in this disease when there is significant striatal atrophy, I did not
observe differences in RBM3 protein levels between HD and WT mice. I then examined the
cortex and found that in contrast to the striatum, RBM3 levels are significantly reduced in the
cortex of HD mice (figure 2.4). As the striatum is affected earlier in HD, I hypothesized the
differences between RBM3 levels in the cortex and striatum may reflect a lower and higher stress
state respectively, but does not necessarily indicate a functional or sufficient stress response.
These results are consistent with my finding that RBM3 protein levels are generally not different
between Q7 and Q111 cells.
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Tables

Sample RBM3 level
0.24
HD1
0.38
HD2
0.40
HD3
0.43
HD4
0.60
HD5
0.62
HD6
0.74
HD7
0.89
HD8
1.03
HD9
1.11
HD10
1.13
HD11
1.18
HD12
1.46
HD13
1.54
HD14
CTRL1
0.61
CTRL2
0.65
CTRL3
0.80
CTRL4
0.82
CTRL5
0.93
CTRL6
0.96
CTRL7
0.96
CTRL8
0.99
CTRL9
1.07
CTRL10
1.07
CTRL11
1.15
CTRL12
1.17
CTRL13
1.20
CTRL14
1.23
CTRL15
1.37

Age
57
52
44
61
78
56
64
56
65
51
59
69
69
56
72
48
42
50
59
57
74
60
48
64
61
83
68
65
54

Sex
F
M
M
M
M
F
M
F
M
F
M
M
M
F
M
F
M
M
M
M
M
M
M
M
M
M
F
M
F

VS Grade
3
3
3
3
2
2
2
2
2
4
3
3
3
3
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A

Repeat Length
Unavailable
Unavailable
Unavailable
43/17
40/17
Unavailable
42/8
46/29
Unavailable
Unavailable
45/18
Unavailable
42/17
45/17
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A

Table 2.1 Overview of HD patient brain sample data set
Overview of Huntington’s disease (HD) and control (CTRL) Brodmann Area 4 motor cortex
sample data set. RBM3 mRNA levels are normalized to HPRT and relative to controls, and do not
appear to correspond to age, sex, Vonsattel grade (VS grade), or CAG repeat length.
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Figures

Human RBM3 mRNA levels

Relative Expression

2.0
1.5
1.0
0.5
0.0

CTRL
Cortex

HD
Cortex

Figure 2.1 RBM3 mRNA expression trends lower in HD cortex with greater variance
RBM3 mRNA levels trend lower in Huntington’s disease (HD) cortex compared to control (CTRL)
cortex (CTRL mean=1, median=0.99, HD mean=0.84, median=0.81, n≥14. Error bars represent
SEM). Variance between the two groups is significantly different (Welch’s t test, F test *p≤ 0.05).
RBM3 expression was normalized to HPRT.
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Figure 2.2 Knockdown of HTT increases Rbm3 in HD but not WT mice
AAV microRNA (miRNA) mediated knock-down of HTT leads to increased Rbm3 mRNA levels in
the striatum of 6-month-old BACHD (HD) but not WT mice (n≥4, one-way ANOVA with Tukey’s
post hoc analysis, ***p≤ 0.001. Error bars represent SEM).
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Figure 2.3 Rbm3 is dysregulated in Q111 cells
A) Rbm3 mRNA is decreased in Q111 (HD) cells compared to Q7 (WT) cells at baseline (37°C).
Additionally, Rbm3 is significantly reduced following incubation at 33°C for 24 hours in HD cells
(n≥3, Student’s t test, ***p≤ 0.001. Error bars represent SEM. Representative results from 3
independent experiments). B) Induction of Rbm3 by incubation at 33°C for 24 hours is blunted in
HD cells compared to WT, as measured by the fold change in expression (Rbm3 mRNA at
33°C/Rbm3 mRNA at 37°C, n≥3, Student’s t test, **p≤ 0.01. Error bars represent SEM). C) RBM3
protein levels are not different between HD and WT cells at 37°C (n=4. Error bars represent
SEM). RBM3 levels were normalized to AKT in the same lane.

26

18 weeks (end stage)
1.5

RBM3/Vinculin

***
1.0

Cortex
WT
HD
Vin

0.5

RBM3

0.0

WT

HD

Cortex

WT

Striatum
WT
HD
130 kD
17 kD

HD

Striatum

N171-82Q model
Figure 2.4 RBM3 is reduced in the cortex of N171-82Q mice
RBM3 protein is decreased in the cortex but not the striatum of mock treated N171-82Q HD mice
at 18 weeks (end stage disease) compared to WT (n≥3, Student’s t test, ***p≤ 0.001. Error bars
represent SEM). Representative blots from two technical replicates. RBM3 levels were
normalized to vinculin in the same lane.
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Figure 2.5 Model of RBM3 dysregulation in HD
A) Model of the RBM3 stress response in the WT and HD setting. RBM3 is reduced at baseline in
HD, and its induction in response to stress is blunted. Dotted blue line represents WT baseline
levels. B) Mutant huntingtin (mHTT) directly, or indirectly through inhibiting transcription factors
(TFs), represses RBM3 expression and RBM3 function, preventing RBM3 from enhancing
mTORC1, thereby contributing to the Huntington’s disease (HD) phenotype.
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Discussion
Taken together, these data indicate that RBM3 is reduced at baseline and its induction in
response to stress is attenuated in the setting of HD (figure 2.5A). RBM3 dysregulation is not
straightforward. Indeed, depending on the model and extent of degeneration, RBM3 levels are
either reduced or the same compared to wild type controls. Further, while Rbm3 mRNA levels are
significantly reduced in Q111 cells, under most conditions protein levels are not different. The
reduction in Rbm3 mRNA but not protein denotes either increased RBM3 translation, possibly as
a compensatory mechanism, or increased protein stability, possibly due to protein modification or
sequestration into mHTT aggregates. Given the blunted induction of Rbm3 expression in Q111
cells under cold stress and the differences in RBM3 turnover, we wondered if the RBM3 stress
response was effectual, i.e. if RBM3 function is impacted in the HD setting.
These results suggest that RBM3 expression is repressed directly or indirectly by mHTT, but that
RBM3 is also induced in response to the increasing stress level in dysfunctional and
degenerating cells (figure 2.5B).

Interestingly, RBM3 was identified as a gene that is

downregulated in an inducible model of HD, and its overexpression prevented polyQ mediated
cell death in vitro1. Of note, RBM3 was rapidly downregulated following induction of mHTT
expression, which is consistent with our model of repression followed by an insufficient RBM3
mediated stress response. While there were no differences in baseline levels of Rbm3 mRNA
between BACHD and WT mice, knockdown of total HTT induced Rbm3 expression in HD but not
WT mice, pointing to mHTT mediated repression of Rbm3. The robust increase in Rbm3
expression points to the possibility that when mHTT levels are decreased, RBM3 is able to mount
a functional stress response, enhancing mTORC1 and mediating synaptic regeneration.
We assessed samples from HD patient cortex, which has less neuronal loss relative to the
striatum, and found that RBM3 mRNA levels trend lower in HD cortex compared to controls.
While this difference is not significant, the difference in variance between the two groups is
significant. After discussing this data with C. Ross, MD, another HD researcher and clinician that
cares for these individuals (personal communication, January 12th, 2016), we felt that one factor
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that may influence RBM3 levels is cause of death. Most HD patients succumb to aspiration
pneumonia, which is typically characterized by reduced blood oxygen saturation leading to
cerebral hypoxia10,11. Moreover, heart disease, which is also associated with cerebral hypoxia, is
the second leading cause of death in HD patients12–14. RBM3 is strongly induced by hypoxia
through unknown mechanisms8. Therefore, the variation in RBM3 mRNA levels may reflect the
extent of RBM3-inducing cellular stress, such as hypoxia, shortly preceding and at the time of
death. Information on cause of death, which would allow me to test this hypothesis, was not
available for this cohort. As we come to understand the pathologic effects of mHTT expression
that occur well before the onset of symptoms, and the effects of mHTT throughout the brain and
in peripheral tissues, rich data sets will be essential to contextualize basic research findings.
RBM3 induction, like other stress response pathways, becomes less robust with aging15,16. HD
has been shown to accelerate epigenetic brain aging as measured by DNA methylation levels
when compared to control and AD brains17. Whether RBM3 dysregulation is upstream or
downstream of accelerated epigenetic aging, it highlights the difficulty in identifying and
translating therapeutic targets due to the compound nature of the pathogenic cascade in HD.
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Materials and Methods
Brain Samples
Coronal sections of human autopsy brain tissues were obtained from unaffected individuals and
patients with Vonsattel grade 2, 3, and 4 HD (Dr. Christopher Ross, Johns Hopkins University;
New York Brain Bank at Columbia University, Alzheimer Disease Research Center, Taub
Institute). Tissues were flash frozen with postmortem intervals ranging from 13 to 49 hr.
Caudate/putamen nuclei were dissected from the frozen tissues and stored at -80°C until they
were processed for RNA extraction using TRIzol.
Cell Culture
Homozygous (Q111), heterozygous (Q7/Q111) and WT (Q7) striatal-like cells18 with full-length
HTT were purchased from the Coriell Institute for Medical Research (Camden). Cells were grown
at 37°C in Dulbecco’s modified Eagle’s medium (Sigma Chemical Co, Saint Louis) supplemented
with 10% fetal bovine serum (FBS), 1% nonessential amino acids, 1% P/S, and 2 mM Lglutamine. For induction of cold stress, cells were incubated at 33°C 24-48 hours before
harvesting.
Animals
All animal protocols were conducted in accordance with the NIH Guide for the Care and Use of
Laboratory Animals and were approved by the Animal Care and Use Committee at The Children’s
Hospital of Philadelphia. N171-82Q19 and BACHD20 murine model lines were obtained from
Jackson Laboratories and maintained on a B6C3F1/J and FVB background respectively. N17182Q mice were genotyped using primers specific for the human HTT transgene, and agematched WT littermates were used as controls for all experiments. Knockdown experiments were
performed in BACHD and WT mice as previously described9. Animals were housed in enriched,
temperature-controlled environments with a 12-hr light/dark cycle. Food and water were provided
ad libitum.
Western Blot
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Mouse brain tissue or cells were lysed in RIPA buffer with protease inhibitors (Complete Mini,
Roche Applied Science, Mannheim) and phosphatase inhibitors (Phos-STOP Phosphatase
Inhibitor Cocktail, Roche Applied Science, Mannheim). Protein concentration was determined by
BCA assay (Pierce, Rockford), and 15–30 mg of protein was reduced and ran on SDS-PAGE on
12% polyacrylamide gels (Biorad, Hercules) and transferred to 0.2 mm Immobilon PVDF
membranes (Millipore, Billerica). Primary antibodies were: RBM3, 1:500, (Proteintech); AKT,
1:1000, (Cell Signaling); Vinculin, 1:1000, (Abcam). Secondary antibodies were HRP-goat antirabbit IgG (Cell Signaling, Danvers). Blots were developed using ECL Plus Western Blotting
Detection System (GE Healthcare, Pittsburg). Densitometry was performed using NIH ImageJ
software. Phospho-independent antibody densities were normalized to vinculin or AKT band in
same lane.
RNA extraction and qPCR Analyses
RNA extraction was performed using TRIzol (Invitrogen) according to the manufacturer’s
instructions. Random-primed first-strand complementary DNA (cDNA) synthesis was performed
using 1000 ng total RNA (High Capacity cDNA Reverse Transcription Kit; Applied Biosystems,
Foster City) per manufacturer’s protocol. For studies with human samples and Q7/Q111 cells,
real-time quantitative PCR (qPCR) was performed on a sequence detection system (Prism
7900HT, Applied Biosystems) using SYBR green PCR mix (Invitrogen, Carlsbad). For studies
using BACHD mice, qPCR was performed as previously described9. Relative gene expression
was determined using the ΔΔCT method, normalizing to human or murine HPRT.
SYBR Primers:
Mouse Rbm3 FW: CTCAACCAATGAGCACGCAC
Mouse Rbm3 REV: TAGCCGAGACGTCACACAAC
Mouse Hprt FW: CGTCGTGATTAGCGATGATG
Mouse Hprt REV: TTTTCCAAATCCTCGGCATA
Human RBM3 FW: TCGACCTGGAGGGTATGGATATGG
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Human RBM3 REV: GGTCATAACCACCCTGGTTTCTGC
Human HPRT FW: TGAGGATTTGGAAAGGGTGT
Human HPRT REV: GCACACAGAGGGCTACAATG
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CHAPTER 3
Overexpression of mRBM3iso1 and RBM3 downstream target RTN3 do not rescue HD
phenotypes

Introduction
RBM3 promotes cell survival in response to multiple forms of stress in vitro and in vivo1–5. In nonneuronal COS7 and neuronal SK-N-SH cells, co-transfection of plasmids expressing a 74 polyQ
mHTT N-terminal fusion protein and human RBM3 significantly reduced cell death through
unknown mechanisms1. In the RML prion murine model, induction of hypothermia for 45 minutes
at 3 and 4 weeks, which is early in the disease course, prevented synapse loss and behavioral
deficits, and significantly increased lifespan. Early cooling resulted in elevated RBM3 levels up to
6 weeks after treatment, however initiating cooling at 5 and 6 weeks failed to induce RBM3 levels
or increase survival. Similarly, in RBM3 knockdown mice, early cooling had no effect on lifespan.
Further, direct overexpression of mouse RBM3 isoform 2 (mRBM3iso2) in the hippocampus of
prion disease and 5XFAD AD mice prevented deficits in synaptic plasticity, and showed the same
benefits as early cooling in the prion disease mice3. Overexpression of mRBM3iso2 increased
global protein synthesis in the hippocampi of prion-infected mice, however this group went on to
identify a single down-stream target of RBM3, the resident ER protein RTN3, as the primary
mediator of RBM3 neuroprotection. Indeed, in prion-infected mice the beneficial effects of cooling
on burrowing behavior, neuronal cell loss, and survival were completely abrogated by RTN3
knockdown6.
The mechanism behind the beneficial effect of RTN3 is unclear, but presumably involves
mitigating ER stress. RBM3 has been shown to directly reduce aberrant PERK/eiF2a/CHOP
mediated ER stress through interactions with PERK4, so it was surprising that RTN3 knockdown
completely abolished the beneficial effect of cooling in prion disease mice. Further, RBM3
overexpression enhances mTORC1 activity in vitro, suggesting RBM3 may promote cell survival
through different mechanisms7. mTORC1 activity is reduced in the striatum of HD patient brain
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and in presymptomatic N171-82Q mice. Restoration of mTORC1 activity via viral vector delivery
of the mTORC1 activator Rheb to the striatum of 7-week-old N171-82Q mice corrects the levels
of a number of well-established disease markers, including DARPP-32 and PGC1-α in MSNs
(Lee 2015). I therefore hypothesized that RBM3 overexpression would be protective in HD mouse
models after in vivo delivery by enhancing mTORC1 and other pro-survival pathways.

Results
mRBM3iso1 overexpression does not rescue HD motor phenotypes
I generated plasmids expressing either mouse RBM3 isoform 1 (mRBM3iso1), mRBM3iso2,
which differs by a single arginine residue, or human RBM3 (hRBM3), under the constitutive CAG
promoter. I transfected N2A cells with these constructs, and based on higher levels of RBM3
expression by western blot (figure 3.1A), I packaged mRBM3iso1 into an adeno-associated virus
(AAV) serotype 1, which efficiently transduces neurons8,9. To determine if overexpressing
mRBM3iso1 alters HD phenotypes, I used the N171-82Q HD model, which expresses the
truncated 171 amino acid N-terminus of human HTT containing an 82 polyQ-stretch driven by the
mouse prion protein promoter. N171-82Q HD mice recapitulate many aspects of HD, including
reduced mTORC1 activity at 6 weeks10, reduced body weight with failure to gain weight starting at
8 weeks, metabolic dysfunction at 10 weeks11, striatal atrophy at 11 weeks, overt motor decline at
12 weeks, and a shortened lifespan of 24 weeks12 (figure 3.1B). I first performed baseline
behavioral assays, including rotarod and open field tests, at 5 weeks of age. I then randomized
groups and performed bilateral injections of AAV1.CAG.mRBM3iso1 or empty vector into the
striatum of 6-week-old HD and WT mice. I overexpressed mRBM3iso1 in both HD and WT mice
so that I could determine if there were any toxicities associated with increased mRBM3iso1 in
healthy mice. I monitored weight and performed rotarod and open field at 10 and 14 weeks and
collected tissue at 18 weeks (figure 3.1C).
To confirm overexpression of mRBM3iso1 I performed western blot and found a ~3-fold increase
in mRBM3iso1 in WT striatum, and a ~5-fold increase in the HD striatum (figure 3.2A).
Interestingly, the significantly higher levels of RBM3 protein in HD striatum is consistent with my
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in vitro data, in which I see Rbm3 mRNA is reduced in Q111 cells compared to Q7 cells, but
protein levels are not different. I next assessed weight gain and found that overexpressing
mRBM3iso1 had no effect on the weight loss phenotype in HD mice. I also observed no
differences between WT mock and WT RBM3 treated mice, indicating mRBM3iso1
overexpression does not adversely affect weight gain (figure 3.2B). I found no difference
between any groups in rotarod performance at 10 weeks, but a significant reduction in
performance in both mock and RBM3 treated HD mice on day 3 and 4 of testing at week 14
(figure 3.2C).
The open field test allows for measurement of a large number of activity variables such as
ambulatory time, distance traveled, vertical time, and so on. It also allows assessment of activity
in discrete zones, so that activity information can be separated, for example, between the
periphery and center zone. Separating the peripheral and center zones is useful as mice can use
the walls of the chamber to support their weight at the periphery, but not at the center. In my
hands, I observe a trend towards reduced total rearing, as measured by vertical time and vertical
counts, at 14 weeks in HD mice compared to WT (figure 3.3A, 3.3B, left). When the peripheral
and center zones are separated, the vertical time and counts are significantly reduced in HD mice
in the center zone(figure 3.3A, 3.3B, middle), while unchanged in the periphery (figure 3.3A,
3.3B, right). In addition, mice spend equal amounts of time in both zones (figure 3.3C),
indicating this phenotype is likely due to motor involvement, rather than depressive or anxiety
type symptoms. Overexpression of mRBM3iso1 has no effect on rearing time in HD or WT mice,
denoting that while mRBM3iso1 overexpression is not overtly toxic, it does not ameliorate the HD
behavioral phenotype.
mRBM3iso1 overexpression does not rescue HD molecular phenotypes
Consistent with my behavioral results, using western blot I found that DARPP-32 levels were
unaffected by mRBM3iso1 overexpression and were significantly reduced in mock and treated
HD mice (figure 3.4A). I next assessed the mTORC1 pathway by looking at phosphorylation,
which denotes activation, of AKT, mTOR, and S6. I found that mRBM3iso1 overexpression
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robustly increases pAKT in HD striatum (figure 3.4B), supporting my hypothesis that RBM3
enhances the mTORC1 pathway, however I found no effect on pmTOR or pS6 levels (figure
3.4C, D). As pS6 is the key downstream mediator of mTORC1 activity in the context of
neuroprotection, these findings were consistent with the lack of behavioral rescue. Initially, these
results were difficult to interpret as pAKT, pS6, and pmTOR levels were not different between HD
mock and WT mock treated mice. However, the robust increase in pAKT but not pmTOR or pS6
in HD RBM3 treated mice directly indicates that the mTORC1 pathway is dysregulated at an
intermediate step between pAKT and mTOR. Interestingly, in N171-82Q hearts mTORC1
dysregulation is dynamic, and Rheb, which is downstream of pAKT and directly activates
mTORC1, is mislocalized at 16 weeks in this model. Future studies will assess if Rheb is similarly
mislocalized in HD striatum, and if this explains why mRBM3iso1 activates pAKT but not its
downstream targets. Of note, mRBM3iso1, which was expressed at lower levels in WT striatum
compared to HD, subtly increased pAKT and pmTOR in WT mice.
RBM3-RTN3 axis is dysregulated in Huntington’s disease
Given that I did not see rescue of any HD phenotype, I next wanted to assess mRBM3iso1
function. RTN3 is a recently identified direct target of RBM3. I therefore measured RTN3 levels by
western blot as a readout of RBM3 function. Consistent with the lack of rescue in my behavioral
studies, I found that mRBM3iso1 overexpression did not increase RTN3 levels in HD or WT
striatum (figure 3.5A). I also found that RTN3 isoform 3 is significantly reduced in both the
murine HD striatum and cortex compared to WT (figure 3.5B). To validate these findings in
another model, I measured RTN3 levels by western blot in Q7 and Q111 cells and found that
RTN3 isoform 3 and isoform 4 are significantly reduced in Q111 cells relative to Q7 cells (figure
3.5C). In the HD cortex, I had observed significantly reduced levels of RBM3, but no differences
in RBM3 levels in the striatum, and hypothesized this indicated induction of RBM3 in response to
the higher levels of stress in the striatum, but not necessarily a functional response. Significantly
reduced levels of RTN3 in N171-82Q cortex and striatum, and in Q111 cells, support this
hypothesis and suggest that RBM3 expression and function are dysregulated in HD. However,
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these results do not explain why overexpression of mRBM3iso1 did not induce RTN3 in WT
striatum.
RTN3 overexpression does not rescue HD phenotypes
Maladaptive ER stress is implicated in HD, and targeting components of this pathway is
protective in murine models13. Further, RTN3 mediates RBM3’s neuroprotective effect in a murine
model of prion disease6. Therefore, because mRBM3iso1 overexpression failed to induce RTN3
and RTN3 is significantly reduced in HD models, I next wanted to investigate if direct
overexpression of mouse RTN3 isoform 3 (mRTN3iso3), which is protective in prion disease,
would ameliorate HD phenotypes. I generated and validated an AAV1.CAG.mRTN3iso3 vector
and initiated a second behavioral study with baseline rotarod performed at 8 weeks, bilateral
injections at 9 weeks, and follow-up behavior at 14 and 18 weeks. I achieved robust
overexpression of mRTN3iso3 (figure 3.6A), which interestingly also increases mRTN3 isoform 4
(data not shown). This treatment had no effect on weight gain or rotarod deficits, suggesting that
restoring RTN3 levels alone is not sufficient to rescue HD phenotypes(figure 3.6B, C).
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Figure 3.1 Construct validation and experimental design
A) Plasmids expressing human RBM3 (hRBM3), mouse RBM3 isoform 1 (mRBM3iso1) and
mouse RBM3 isoform 2 (mRBM3iso2) driven by the CAG promoter were transfected into N2A
cells. Protein was collected 24 hours post-transfection and analyzed by Western blot. Plasmid
construct includes AAV2 inverted tandem repeats (ITR) and the bovine growth hormone polyA tail
(bGHpA). Quantification of blots shown in fig.2A (n≥3, one-way ANOVA with Dunnett’s post hoc
analysis, ****p≤ 0.0001). B) The transgenic N171-82Q HD mouse model, expressing the first 171
amino acids of human HTT with an 82 CAG expansion driven by the mouse prion promoter,
recapitulates many disease phenotypes. This is a quickly progressing model with all mice
succumbing to the disease by 24 weeks. C) Rotarod and open field activity chamber were
performed at 5 weeks of age, bilateral stereotactic injections of AAV1.mRBM3iso1 or empty
vector were performed directly into the striatum at a dose of 5µl of 3x1012 vector
genomes/ml/hemisphere. A 10% AAV1.eGFP spike was co-injected to allow for visualization of
the injected area. Rotarod and open field activity chamber were performed at 10 and 14 weeks,
and tissue was collected at 18 weeks.
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Figure 3.2 mRBM3iso1 overexpression does not rescue HD behavioral phenotypes
A) AAV1 mediated mRBM3iso1 overexpression 12 weeks post-injection in 18-week-old N17182Q HD and WT murine striatum. Significantly higher levels of RBM3 overexpression was
achieved in HD striatum compared to WT (n≥5). B) RBM3 overexpression does not affect weight
gain (grams, g) in HD or WT mice (n≥14). D) RBM3 overexpression does not affect rotarod
performance in HD or WT mice at 14 weeks of age. The change in latency to fall from 5-week
baseline is reported (n≥14). All p values are compared to WT Mock unless noted otherwise. For
A-C one-way ANOVA with Tukey’s post hoc analysis, ****p≤ 0.0001, **p≤ 0.01, *p≤ 0.05. Error bars
represent SEM.
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Figure 3.3 mRBM3iso1 overexpression does not rescue HD activity phenotype
A) Rearing duration is significantly reduced in the center zone of the open field activity chamber in
14-week-old HD mice compared to WT. Rearing duration is unaffected in the peripheral zone. B)
The number of rearing events are significantly reduced in the center zone of the open field activity
chamber in 14-week-old HD mice compared to WT. Rearing events are unaffected in the
peripheral zone. C)14-week-old HD and WT mice do not differ in their total ambulatory time and
spend similar amounts of time in the center and peripheral zone. All activity variables are
unaffected by RBM3 overexpression in both HD and WT mice. Activity of individual mice
(n≥14/group) was measured over a period of 30 minutes. All p values are compared to WT Mock
unless noted otherwise. For A-C one-way ANOVA with Tukey’s post hoc analysis, **p≤ 0.01, *p≤
0.05. Error bars represent SEM.
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Figure 3.4 mRBM3iso1 overexpression does not rescue HD molecular phenotypes
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Blots were run in triplicate, with samples loaded in a different order between each blot.
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Figure 3.6 RTN3 overexpression does not rescue HD phenotypes
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injected, left (L), uninjected) stereotactic injection into the striatum of WT mice, (n=3, Student’s t
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bars represent SEM.
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Discussion
Based on previous findings that overexpression of mRBM3iso2 was protective in Alzheimer and
prion mouse models3, and that overexpression of hRBM3 was protective in an in vitro model of
HD1, I generated constructs to express hRBM3, mRBM3iso1, and mRBM3iso2. Human and
mouse RBM3 share 94% identity, and mRBM3iso1 and mRBM3iso2 differ only by the addition of
a single arginine residue in the arginine rich domain of isoform 1. At this region, hRBM3 includes
the additional arginine residue, and thus is more similar to mRBM3iso1. In vitro overexpression
studies indicate that mRBM3iso1 is more highly enriched in the nucleus and mRBM3iso2 is more
highly enriched in the cytoplasm7, however there are no known differences in function between
the two isoforms. I therefore selected mRBM3iso1 for vector production based on achieving the
highest level of overexpression with this construct in vitro.
In contrast to previous in vitro and in vivo studies, I found that overexpression of mRBM3iso1 had
no effect on disease progression in the N171-82Q HD murine model. Seemingly consistent with
these results, mRBM3iso1 overexpression did not increase RTN3 levels as expected. This
suggested that while I achieved a significant increase in mRBM3iso1 levels, mRBM3iso1 was not
necessarily fully functional. Of note, modest increases (2-4 fold) in mRBM3iso2 expression, on
par with our yields, rescued neuropathologic and behavioral phenotypes in 5XFAD and prioninfected mice. Further, even transient increases in RBM3 significantly prolonged survival in prion
disease mice. Therefore, while it is possible that a different AAV1.mRBM3iso1 dose could yield
different results, I believe this is unlikely.
Given RTN3’s critical role in stabilizing ER architecture and membrane trafficking, that RTN3
overexpression is protective in the setting of prion disease, and that RTN3 is significantly reduced
in our HD models, the next logical step was to directly overexpress RTN3. Despite robust
overexpression of RTN3, I saw no effect on weight gain or motor deficits in the N171-82Q model,
indicating that boosting RTN3 levels alone is not sufficient to alter HD phenotypes. It is possible
that 9 weeks is too late in the disease progression, and earlier intervention with RTN3 could
prevent, rather than reverse, disease phenotypes. However RTN3 may play a more important
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role in the setting of prion disease, where prolonged ER stress and reduced translation are
central to disease pathology14,15.
Though RTN3 expression is clearly affected in HD, this does not account for my finding that
mRBM3iso1 overexpression did not increase RTN3 levels in WT mice. As previous in vivo studies
were performed using direct overexpression of mRBM3iso2 in the hippocampus, I wondered if
there might be isoform or cell specific differences in RBM3 function. While the role of RTN3 in HD
pathogenesis is unclear, mTORC1 is emerging as a promising therapeutic target in HD. My
current studies indicate that RBM3 likely enhances mTORC1 at or upstream of AKT. Previous
studies used overexpression of constitutively active Rheb (caRheb) to restore mTORC1 activity in
N171-82Q mice10. If Rheb is mislocalized in the striatum, as it is in N171-82Q heart tissue16, then
it is possible that direct overexpression of caRheb is sufficient to overcome Rheb mislocalization.
Consequently, if RBM3 acts on AKT activation, but does not affect Rheb mislocalization, this
would explain why overexpressing mRBM3iso1 was not beneficial in N171-82Q mice.
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Materials and Methods
Animals
All animal protocols were conducted in accordance with the NIH Guide for the Care and Use of
Laboratory Animals and were approved by the Animal Care and Use Committee at The Children’s
Hospital of Philadelphia. N171-82Q12 HD murine model lines were obtained from Jackson
Laboratories and maintained on a B6C3F1/J background. Mice were genotyped using primers
specific for the human HTT transgene, and age-matched WT littermates were used as controls
for all experiments. Animals were housed in enriched, temperature-controlled environments with
a 12-hr light/dark cycle. Food and water were provided ad libitum.
Western Blot
Mouse brain tissue or cells were lysed in RIPA buffer with protease inhibitors (Complete Mini,
Roche Applied Science, Mannheim) and phosphatase inhibitors (Phos-STOP Phosphatase
Inhibitor Cocktail, Roche Applied Science, Mannheim). Protein concentration was determined by
BCA assay (Pierce, Rockford), and 15–30 mg of protein was reduced and ran on SDS-PAGE on
12% polyacrylamide gels (Biorad, Hercules) and transferred to 0.2 mm Immobilon PVDF
membranes (Millipore, Billerica). Primary antibodies were: DARPP-32, 1:1,000; S6, 1:1,000;
phospho-S6, S235/236, 1:2,000; mTOR, 1:1,000; phospho-mTOR, S2448, 1:1000, AKT, 1:1000;
phospho-AKT, S473; (Cell Signaling); RBM3, 1:500, (Proteintech); RTN3 C-Terminal, 1:1000;
Vinculin, 1:1000, (Abcam). Secondary antibodies were HRP-goat anti-mouse IgG and HRP-goat
anti-rabbit IgG (Cell Signaling, Danvers). Blots were developed using ECL Plus Western Blotting
Detection System (GE Healthcare, Pittsburg) and exposed to film for images. Densitometry was
performed using NIH ImageJ software. Densities of bands detected by phospho-antibodies were
normalized to densities of bands detected by phospho-independent antibodies in same lane.
Phospho-independent antibody densities were normalized to vinculin or AKT band in same lane.
RNA extraction and qPCR Analyses
RNA extraction was performed using TRIzol (Invitrogen, Carlsbad) according to the
manufacturer’s instructions. Random-primed first-strand complementary DNA (cDNA) synthesis
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was performed using 1000 ng total RNA (High Capacity cDNA Reverse Transcription Kit; Applied
Biosystems, Foster City) per manufacturer’s protocol. Real-time PCR was performed on a
sequence detection system (Prism 7900HT, Applied Biosystems) using SYBR green PCR mix
(Invitrogen). Relative gene expression was determined using the ΔΔCT method, normalizing to
human or murine HPRT.
Plasmids and AAVs
AAV serotype 1 was used for these studies. The human RBM3 cDNA (NM_006743) was
amplified from a HEK293 cell cDNA library, and the mouse Rbm3 (isoform 1, NM_016809.6;
isoform 2, NM_001166410.2) and Rtn3 (NM_053076.3) cDNA was amplified from a Q7 cell cDNA
library. The transgenes or an eGFP reporter gene were inserted into the pFB.AAV.CAG.bHGpA
plasmid containing AAV2 ITRs (Iowa Vector Core, Iowa City, IA) and were then used to produce
AAV vectors by the Children’s Hospital of Philadelphia (CHOP) Research Vector Core
(Philadelphia, PA). Titers (measured in viral genomes/mL) were determined by qPCR. All
constructs were verified by Sanger Sequencing (CHOP Napcore, Philadelphia, PA).
Cell Culture and Transfections
Homozygous (Q111), heterozygous (Q7/Q111) and WT (Q7) striatal-like cells17 with full-length
HTT were purchased from the Coriell Institute for Medical Research (Camden). These cells were
grown at 37°C in Dulbecco’s modified Eagle’s medium (Sigma Chemical Co, Saint Louis)
supplemented with 10% fetal bovine serum (FBS), 1% nonessential amino acids, 1% P/S, and 2
mM L-glutamine. N2A cells were cultured under standard conditions in DMEM supplemented with
10% FBS and 1% P/S, and transfected with Lipofectamine 2000 (Thermo Fisher, Waltham)
according to the manufacturer’s instructions.
Injections
Mice were deeply anaesthetized with isoflurane and immobilized in a stereotaxic frame installed
with a microinjection robot for motorized injections. Mice were injected in the striatum via a
Hamilton syringe using the following coordinates: AP, 0.86 mm; ML, ± 1.8mm; and DV, -2.5 mm
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(from brain) relative to bregma. Each mouse received 5 µL of vector per hemisphere at a
concentration of 3e+12 vg/ml for AAV1.mRBM3iso2 and 1e+12 vg/ml for AAV1.mRTN3iso3, with
a 10% AAV1.eGFP vector spike for visualization of the injected area. Vectors were infused at a
rate of 0.25 µL/min with a 5 minute wait time post-infusion prior to withdrawal of the trochanter.
Empty AAV1 vector (with a 10% AAV1.eGFP spike) or AAV1.eGFP was used as a control as
indicated. Mice were sacrificed at indicated ages using standard approved methods.
Accelerating Rotarod
Male N171-82Q mice were tested for baseline motor function at 5 weeks of age and then at
subsequent time points as indicated. One the first day of testing, mice were first habituated on the
rotarod for 4 min and rested for 1 hr. The tests were conducted three trials per day (with 30 min of
rest between trials) for 4 consecutive days. For each trial, mice were placed on the rod that
accelerates from 4 to 40 rotations per min over 4 min and then speed maintained at 40 rpm.
Latency to fall (or if mice hung on for two consecutive rotations without running) was used as a
rating of motor performance. The trials were stopped at 300 s, and mice remaining on the rotarod
at that time were scored as 300 s. Data from the three trials for each group on each day are
presented as means ± SEM. Mice were always tested in the light phase of the light/dark cycle,
and habituated to the testing room for 1 hour prior to testing.
Open Field Activity Chamber
Male N171-82Q mice were tested for baseline activity at 5 weeks of age and then at subsequent
time points as indicated. Activity of individual mice was measured over 30 minutes. Mice were
always tested in the light phase of the light/dark cycle, and habituated to the testing room for 1
hour prior to testing.
Mouse Brain Isolation
Mice were sacrificed at indicated ages by anesthetizing with a ketamine/xylazine mixture,
followed by transcardial perfusion with 15mL of ice-cold 0.9% phosphate-buffered saline (PBS).
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Brains were quickly removed from the skull. Those used for protein or RNA analyses were
microdissected and flash-frozen in liquid nitrogen and stored at -80°C until processed.
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CHAPTER 4

RBM3 may have cell type and isoform specific functions

Introduction
The protective effect of RBM3 induction in response to stress has been appreciated for nearly two
decades; however, we are only recently beginning to elucidate how RBM3 mediates this effect.
Overexpression of RBM3 enhances global protein synthesis under normothermic and
hypothermic conditions, which is thought to be broadly protective. RBM3 influences translation in
several ways. During the initiation step of protein synthesis, RBM3 enhances ribosomal subunit
association by tightly binding to the 60S ribosomal subunit in an RNA-independent manner,
increasing 80S monosome and polysome levels1. RBM3 overexpression also increases
phosphorylation of 4EBP1 through unknown mechanisms, which causes it to dissociate from
eIF4E thereby promoting translation initiation2. Similarly during ER stress, RBM3 interacts with
PERK in an RNA-dependent manner to decrease phosphorylation of eIF2a, likewise promoting
initiation, as well as decreasing CHOP mediated apoptosis3. RBM3 also regulates microRNA
(miRNA) biogenesis, and while its effect on global miRNA expression is controversial, it enhances
anti-apoptotic miRNA expression while repressing pro-apoptotic miRNAs1,4. In the setting of prion
disease, RTN3, a downstream target of RBM3, is the primary mediator of neuroprotection in
mouse hippocampus. Mechanistically, RBM3 directly binds the 5’UTR of RTN3 and increases its
translation5.
In my studies described in the previous chapter, I found that overexpression of mRBM3iso1 in HD
and WT murine striatum did not increase RTN3 levels as expected. I considered several potential
explanations. First, there may be an early dynamic increase in RTN3 that I was simply missing at
12 weeks post-injection of AAV1.mRBM3iso1. Second, it is possible that mRBM3iso1 and
mRBM3iso2 differentially regulate RTN3 induction. Third, RBM3 regulation of RTN3 might vary
between cell types, as previous work was done in HEK293 cells and in mouse hippocampus,
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while my experiments were done in the striatum. My previous studies, in which I found
mRBM3iso1 overexpression significantly increased pAKT levels in HD striatum, also supported
my hypothesis that RBM3 enhances the mTORC1 pathway. However, this effect was subtle in
WT mice, and warranted further investigation. To test these hypotheses, I performed short term
overexpression studies of both mRBM3iso1 and iso2, so I could directly compare their effects on
RTN3 and mTORC1 at an earlier timepoint in vivo. I also compared the effect of cold stress on
RTN3 and mTORC1 in different cell types in vitro.

Results
Differential induction of RTN3
I generated AAV1.CAG.mRBM3iso2 and overexpressed either mRBM3iso1 or mRBM3iso2 in
both N171-82Q HD and WT striatum by direct stereotactic injection of 8-week-old mice and
collected tissue 4 weeks post injection. While I achieved a robust increase in mRBM3iso1 and
mRBM3iso2 (figure 4.1A), RTN3 levels were not affected as assessed by western blot (figure
4.1B, C). These results indicate that differences in RBM3 isoforms do not explain why RTN3 is
not induced in the striatum, nor do I appear to be missing an early dynamic RTN3 response at 4
weeks post-injection. As I did not observe increased RTN3 in vivo I next sought to recapitulate
RTN3 induction by cold stress in HEK293 and in the striatal-like cells. After 48 hours of cold
stress at 33°C, I found a 2-3-fold increase in RBM3 levels in HEK293, Q7 and Q7/Q111
(heterozygous) striatal-like cells by western blot (figure 4.1D, F). Intriguingly, I only observed an
increase in RTN3iso4 in HEK293 cells and not in the striatal-like cells, regardless of genotype
(figure 4.1E). Further, RTN3iso4 levels significantly decreased in the Q7/Q111 cells following
cold stress. I found similar results in HEK293, Q7, and Q111 cells after incubation for 24 hours at
33°C (data not shown). Of note, I show RTN3iso4 levels here as HEK293 cells have very low
levels of RTN3iso3, but RTN3iso3 is similarly affected by cold stress in the Q7 and Q7/Q111 cells
(data not shown). Taken together, these data suggest that the RBM3-RTN3 axis may function
differently in the striatum compared to other brain regions or peripheral tissues.
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Cold stress and mRBM3iso2 overexpression enhance mTORC1
We previously demonstrated that inhibition of mTOR exacerbates disease phenotypes in Q111
cells and restoration of mTORC1 activity rescues HD phenotypes in N171-82Q mice6. RBM3
overexpression enhances p4EBP1 levels, a marker of mTORC1 activity, in vitro, and both
proteins play key roles in synapse regeneration, suggesting a mechanistic interaction2. I therefore
assessed the effect of cold stress on mTORC1 pathway activity by measuring phosphorylation of
mTOR and S6 in the striatal-like cells. Phosphorylated S6 is a well-established marker of
mTORC1 activity7 and an effector of mTORC1 mediated neuronal regeneration8. Consistent with
my hypothesis, I found that pmTOR and pS6 are significantly enhanced by cold stress in Q7 and
Q7/Q111 cells.
To further probe the effects of RBM3 on the mTORC1 pathway, I then measured pAKT, pmTOR
and pS6 after 4 weeks overexpression of mRBM3iso1 or mRBM3iso2 in the striatum of HD and
WT mice. Remarkably, at 4 weeks post-injection I found that mRBM3iso2 overexpression
enhances pAKT, pmTOR and pS6 in both HD and WT mice, while mRBM3iso1 has no effect.
Overexpression of mRBM3iso2 also increased total mTOR and total S6 levels in WT and HD
mice, significantly so in HD striatum. This is in contrast to my finding that overexpression of
mRBM3iso1 significantly enhances only pAKT levels at 12 weeks post-injection. These results
suggest that mRBM3iso1 and iso2 play different functional or temporal roles in enhancing the
mTORC1 pathway, an unexpected result give that mRBM3 isoform 1 and 2 differ only by the
addition of a single arginine residue.
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Figure 4.1 Differential RTN3 induction
A) AAV1 mediated overexpression of mRBM3iso1 or mRBM3iso2 in N171-82Q HD and WT
striatum 4 weeks post-injection in 12-week-old mice (top, n≥4). B) Robust overexpression of
mRBM3iso1 and mRBM3iso2 does not affect RTN3 isoform 3 (RTNiso3) levels in HD or WT
mice. C) Representative blot. Blots were run in duplicate, with samples loaded in a different order
between each blot. D) RBM3 protein levels following 48 hours (48h) incubation at 33°C in
HEK293 cells and striatal-like Q7 (WT) and Q7Q111 cells (HD, heterozygous) (n=4, Student’s t
test, ***p≤ 0.001, **p≤ 0.01). E) Moderate cold stress increases RTN3 isoform 4 (RTN3iso4) protein
levels in HEK293 cells but not in the striatal-like cells (n=4, Student’s t test, **p≤ 0.01). F)
Representative blot. Blots were run in duplicate, with samples loaded in a different order between
each blot. For all graphs error bars represent SEM.
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Figure 4.2 Cold stress significantly increases mTORC1 activity
Incubation at 33°C for 48 hours (48h) significantly enhances phospho-mTOR (pmTOR) (A) and
phospho-S6 (pS6) levels (B) in both striatal-like Q7 (WT) and Q7Q111 (HD, heterozygous) cells
compared to normothermic controls. Total levels of mTOR are not significantly affected by cold
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Figure 4.3 Short term overexpression of mRBM3iso2 enhances mTORC1 activity
Overexpression of mouse RBM3 isoform 2 (iso2) but not mouse RBM3 isoform 1 (iso1) enhances
pAKT (A), pmTOR (B), and pS6 (C) 4 weeks post-injection in 12-week-old N171-82Q HD and WT
murine striatum. Total mTOR (B) and S6 (C) are significantly increased in mRBM3iso2 treated
HD mice (n≥4, one-way ANOVA with Tukey’s post hoc analysis, *p≤ 0.05. Error bars represent
SEM). Blots were run in duplicate (A), with samples loaded in a different order between each blot.
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Discussion
While the relevance of RTN3 deficiency to HD pathology remains unclear, I was still curious why
mRBM3iso1 overexpression did not induce RTN3 in HD or WT striatum. I hypothesized that there
might be an early increase in RTN3 levels that normalized by 12 weeks post-injection, or that
there may be differences between mRBM3iso1 and iso2 function. When I overexpressed either
isoform in HD or WT striatum and looked 4 weeks post-injection (peak of gene expression from
AAV vectors), I saw no effect on RTN3 levels, indicating that a temporal response or differences
in RBM3 isoform were unlikely explanations for our findings. I also wondered if the RBM3-RTN3
axis might be different in the striatum, as previous work demonstrating RBM3 increases RTN3
translation was done in murine hippocampus and HEK293 cells. In an effort to recapitulate
previous findings, I induced cold stress in HEK293, Q7, and Q7/Q111 cells and measured RBM3
and RTN3 levels. As expected, 48 hours of cold stress increased RBM3 levels in all cell lines, but
surprisingly, only increased RTN3 levels in the HEK293 cells, suggesting that RBM3 differentially
induces RTN3 depending on cell type. This finding points to the complexity of RBM3 function as
both a stress response and RNA-binding protein, but may also point to fundamental differences in
MSNs that could in part explain why the striatum is so vulnerable in HD, and warrants further
investigation.
Finally, we have previously demonstrated that enhancing mTORC1 activity in the striatum and
heart is beneficial in N171-82Q mice, and wanted to assess whether cold stress or RBM3
overexpression altered this pathway. While 48 hours of cold stress had no effect on RTN3 levels,
intriguingly, it robustly enhanced the mTORC1 pathway. Importantly, in both Q7 and Q7Q111
cells cold stress increased pS6 levels, which is both a common read out for mTORC1 activity and
mediator of synaptic regeneration. The two mouse RBM3 isoforms are expressed throughout the
brain at roughly equal amounts as measured by two-dimensional immunoblots2, and there are no
reported differences in their expression in response to cold stress. It is therefore possible that one
or both isoforms contribute to mTORC1 activation during cold stress. Of note, cold stress in
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HEK293 cells, which are of human origin, also increased pmTOR and pS6 levels (data not
shown), indicating this response is not unique to murine cell lines.
To further parse the effect of each isoform in vivo, I then looked at this pathway in N171-82Q HD
and WT striatum. Surprisingly, at 4 weeks post-injection with either mRBM3iso1 or iso2, I found
that overexpression of mRBM3iso2, but not iso1, enhanced mTORC1 activity. I had earlier
observed significantly increased pAKT levels 12 weeks post-injection of mRBM3iso1 in HD mice,
with no effect on pmTOR or pS6, and hypothesized this was due to mislocalization of Rheb. Like
many cellular processes that become progressively dysfunctional in HD, it is possible that
mislocalization of Rheb does not occur until mid to late-stage disease, which would in part explain
differences in mTORC1 induction at 12 weeks versus 18 weeks of age.
However, this does not account for why mRBM3iso1 increased pAKT at 12 weeks post-injection
but not at 4 weeks post-injection. In overexpression studies in vitro, mRBM3iso1 was enriched in
the nucleus while mRBM3iso2 was enriched in the cytoplasm, particularly at dendritic branch
points2. Differential localization may influence RBM3 function or timescale, with mRBM3iso2
acting on local translation and protein-protein interactions, and mRBM3iso1 orchestrating broader
transcriptional/post-transcriptional changes, for example. It is important to note that I am only
capturing a snapshot of mTORC1 dynamics, and further studies at additional timepoints are
needed to appreciate bona fide differences between RBM3 isoform function and dynamics. In
sum, previous groups have shown that overexpression of both mRBM3iso1 or iso2 enhance
global protein synthesis in vitro; however, our results indicate the two isoforms have a different
temporal or functional role in vivo that has not previously been reported.
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Materials and Methods
Animals
All animal protocols were conducted in accordance with the NIH Guide for the Care and Use of
Laboratory Animals and were approved by the Animal Care and Use Committee at The Children’s
Hospital of Philadelphia. N171-82Q HD murine model lines were obtained from Jackson
Laboratories and maintained on a B6C3F1/J background. Mice were genotyped using primers
specific for the human HTT transgene, and age-matched WT littermates were used as controls
for all experiments. Animals were housed in enriched, temperature-controlled environments with
a 12-hr light/dark cycle. Food and water were provided ad libitum.
Western Blot
Mouse brain tissue or cells were lysed in RIPA buffer with protease inhibitors (Complete Mini,
Roche Applied Science, Mannheim) and phosphatase inhibitors (Phos-STOP Phosphatase
Inhibitor Cocktail, Roche Applied Science, Mannheim). Protein concentration was determined by
BCA assay (Pierce, Rockford), and 15–30 mg of protein was reduced and ran on SDS-PAGE on
12% polyacrylamide gels (Biorad, Hercules) and transferred to 0.2 mm Immobilon PVDF
membranes (Millipore, Billerica). Primary antibodies were: DARPP-32, 1:1,000; S6, 1:1,000;
phospho-S6, S235/236, 1:2,000; mTOR, 1:1,000; phospho-mTOR, S2448, 1:1000, AKT, 1:1000;
phospho-AKT, S473; (Cell Signaling); RBM3, 1:500, (Proteintech); RTN3 C-Terminal, 1:1000;
Vinculin, 1:1000, (Abcam). Secondary antibodies were HRP-goat anti-mouse IgG and HRP-goat
anti-rabbit IgG (Cell Signaling, Danvers). Blots were developed using ECL Plus Western Blotting
Detection System (GE Healthcare, Pittsburg) and exposed to film for images. Densitometry was
performed using NIH ImageJ software. Densities of bands detected by phospho-antibodies were
normalized to densities of bands detected by phospho-independent antibodies in same lane.
Phospho-independent antibody densities were normalized to vinculin or AKT band in same lane.
Plasmids and AAVs
AAV serotype 1 was used for these studies. The mouse Rbm3 (isoform 1, NM_016809.6; isoform
2, NM_001166410.2) cDNA was amplified from a Q7 cell cDNA library. The transgenes or an
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eGFP reporter gene were inserted into the pFB.AAV.CAG.bHGpA plasmid containing AAV2 ITRs
(Iowa Vector Core, Iowa City, IA) and were then used to produce AAV vectors by the Children’s
Hospital of Philadelphia (CHOP) Research Vector Core (Philadelphia, PA). Titers (measured in
viral genomes/mL) were determined by qPCR. All constructs were verified by Sanger Sequencing
(CHOP Napcore, Philadelphia, PA).
Cell Culture and Transfections
Homozygous (Q111), heterozygous (Q7/Q111) and WT (Q7) striatal-like cells9 with full-length
HTT were purchased from the Coriell Institute for Medical Research (Camden). These cells were
grown at 37°C in Dulbecco’s modified Eagle’s medium (Sigma Chemical Co, Saint Louis)
supplemented with 10% fetal bovine serum (FBS), 1% nonessential amino acids, 1% P/S, and 2
mM L-glutamine. HEK293 cells were cultured under standard conditions in DMEM supplemented
with 10% FBS and 1% P/S. For induction of cold stress, cells were plated and kept at 37°C
overnight, and then incubated at 33°C 24-48 hours before harvesting.
Injections
Mice were deeply anaesthetized with isoflurane and immobilized in a stereotaxic frame installed
with a microinjection robot for motorized injections. Mice were injected in the striatum via a
Hamilton syringe using the following coordinates: AP, 0.86 mm; ML, ± 1.8mm; and DV, -2.5 mm
(from brain) relative to bregma. Each mouse received 5 µL of vector per hemisphere at a
concentration of 3e+12 vg/ml, with a 10% AAV1.eGFP vector spike for visualization of the
injected area. Vectors were infused at a rate of 0.25 µL/min with a 5 minute wait time postinfusion prior to withdrawal of the trochanter. Empty AAV1 vector (with a 10% AAV1.eGFP spike)
or AAV1.eGFP was used as a control as indicated. Mice were sacrificed at indicated ages using
standard approved methods.
Mouse Brain Isolation
Mice were sacrificed at indicated ages by anesthetizing with a ketamine/xylazine mixture,
followed by transcardial perfusion with 15mL of ice-cold 0.9% phosphate-buffered saline (PBS).
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Brains were quickly removed from the skull. Those used for imaging studies were fixed whole in
4% paraformaldehyde overnight at 4°C followed by placement in a 30% sucrose/0.05% sodium
azide solution for cryoprotection at 4°C. Those used for protein or RNA analyses were
microdissected and flash-frozen in liquid nitrogen and stored at -80°C until processed.
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CHAPTER 5
Discussion

Overview
The HTT gene was first mapped to chromosome 4 in 1983, and through tremendous collaborative
and innovative research the CAG repeat expansion was identified as the disease causing
mutation ten years later1,2. Since then, pathologic cascades induced by mHTT expression have
been described in detail, with new mechanisms and insights continuing to be identified. For
example, mTORC1 activation has recently emerged as a therapeutic target in HD, with potential
to ameliorate both central and peripheral disease phenotypes3,4. Prior to these studies it was
actually thought that mTORC1 inhibition would be beneficial in HD5,6. While there is currently no
treatment for HD, anti-sense oligonucleotide and AAV mediated knock-down of HTT mRNA have
shown great promise in preclinical models and are progressing to the clinic7–10. However, these
interventions are specific to HD and cannot be translated to other more common
neurodegenerative diseases, and further, may be augmented by combination therapy.
Indeed, HD shares many features with Alzheimer’s and Parkinson’s disease, such as early
synapse loss, late onset, protein misfolding and aggregation, and selective regional degeneration
of the brain despite widespread expression of the pathological protein. Therefore, identifying
broadly neuroprotective proteins that can work in combination with HD specific treatments, and
can potentially provide benefit in other disease settings, is of interest. RBM3 was first implicated
in neurodegenerative disease nearly two decades ago, when it was shown to be transcriptionally
repressed in an HD cell model, and to prevent polyQ mediated toxicity when overexpressed
through unknown mechanisms11. More recently, it was discovered that hippocampal
overexpression of RBM3 in Alzheimer and prion murine models is neuroprotective and in the
setting of prion disease is mediated by RTN3, a downstream target of RBM312. However, RBM3
also enhances global protein synthesis, directly reduces aberrant ER stress, and has been linked
to mTORC1 activation, indicating RBM3 may be protective in different disease contexts through

66

different mechanisms. Whether RBM3 dysregulation is bona fide in HD, and how it mitigates
polyQ toxicity remains unclear.
Here, I show that RBM3 and RTN3, a downstream target of RBM3, are dysregulated in in vitro
and in vivo models of HD. I find that overexpressing mRBM3iso1 in the striatum of HD mice does
not rescue disease phenotypes. I also find that overexpressing mRBM3iso1 or iso2 in the
striatum does not increase RTN3 levels as expected, and that RTN3 overexpression alone is not
beneficial in vivo. Further, I provide evidence that cold stress, and mRBM3iso1 or iso2
overexpression, activate components of the mTORC1 pathway. Interestingly, my findings point to
the possibility that mRBM3iso1 and iso2, though only differing by a single arginine residue,
regulate mTORC1 activity through different temporal or functional mechanisms. My combined
work indicates that the RBM3-RTN3 axis may function differently in the striatum, possibly
contributing to striatal vulnerability in HD, and that while mRBM3iso1 enhances upstream
components of the mTORC1 pathway, it is insufficient to rescue HD phenotypes.

RBM3 is dysregulated in HD
RBM3 is expressed at basal levels throughout the brain, and is induced in response to stress that
alters the proteostasis network, such as hypothermia and hypoxia13,14. RBM3 induction in
response to cold stress is dysregulated in AD and prion-infected mice. In contrast, its baseline
expression is repressed in an HD model in vitro. This suggests that the mechanism behind RBM3
dysregulation is different between these disease settings. Distinguishing between baseline and
induced expression is a general challenge when studying highly sensitive stress response
proteins and is further complicated by the poor understanding of RBM3 transcriptional regulation.
Characterizing RBM3 dysregulation was challenging given that differences in the environment
and the disease models (in vitro versus in vivo, polyQ length etc.) could induce variances in
cellular stress, which could differentially impact RBM3 levels. In HD patient cortex, I found that
RBM3 mRNA trends lower and has significantly higher variability in its expression level compared
to controls. Using immortalized striatal-like cells, I found that Rbm3 mRNA is significantly reduced

67

at baseline and its induction by cold stress is blunted in Q111 cells compared to Q7 cells, but
interestingly, RBM3 protein levels generally are not different. Of note, RBM3 can undergo posttranslational modification15, and it is possible that it is aberrantly modified in the HD setting. In
BACHD mice, ~50% knockdown of total HTT (mutant HTT from the human transgene; WT Htt
from the mouse alleles) in the striatum robustly increases Rbm3 mRNA in HD but not WT mice,
indicating mHTT directly or indirectly represses Rbm3 expression. RBM3 protein is significantly
reduced in late-stage N171-82Q cortex compared to WT, but despite its inducibility upon mHTT
knockdown in the striatum of BACHD mice, RBM3 protein levels are not different in the striatum.
In each of my experimental settings, RBM3 levels were either the same or reduced compared to
wild type controls. The blunted induction of Rbm3 in Q111 cells in response to stress indicates
that the RBM3 stress response is repressed but not totally abrogated by mHTT expression,
otherwise cold stress would have no effect on Rbm3 levels. The over 2-fold increase in Rbm3
expression following knockdown of total HTT in BACHD but not WT mice further points to mHTT
mediated repression of RBM3 at the level of transcription. Of note, knockdown of mHTT is
beneficial in this model, raising the possibility that when RBM3 is de-repressed it mediates a
protective response and aids in improving HD pathology. This led me to hypothesize that RBM3
is induced by the widespread cellular dysfunction that accumulates in HD, but RBM3 expression
is also directly repressed by mHTT, ultimately leading to an insufficient stress response that
cannot overcome mHTT toxicity. This model of RBM3 dysregulation, highlighted in Fig 5.1,
accounts for why in some settings RBM3 levels are not different between HD and controls. For
example, as the striatum is affected more prominently than the cortex in HD (i.e. has higher
accumulated stress), this would explain why RBM3 levels are not different in the striatum at late
stage in N171-82Q mice, but are significantly reduced in the relatively less stressed cortex
compared to WT mice. Indeed, if RBM3 was not repressed, I would expect to observe higher
levels in the HD setting than in controls.
Further complicating the mechanism of RBM3 dysregulation in HD, I also observed discrepancies
between Rbm3 mRNA and protein levels in HD models. In the Q111 cells, while Rbm3 mRNA is
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significantly reduced compared to Q7 cells, protein levels are not different. This indicates either
increased RBM3 translation or increased protein stability, possibly due to protein modification or
sequestration into mHTT aggregates. These results are consistent with my AAV overexpression
studies, where I achieved significantly higher levels of RBM3 expression in HD striatum
compared to WT. The ability of mHTT aggregates to sequester proteins has been described, and
contributes to the complex loss-of-function phenotype in HD16,17. My results suggest RBM3
function is also dysregulated in HD, which is supported by my finding that RTN3, a downstream
target of RBM3, is significantly, and consistently, reduced in Q111 cells compared to Q7 cells,
and in both the cortex and striatum of N171-82Q mice compared to WT.

RBM3 overexpression lead to unexpected results
Overexpression of RBM3 is protective against a number of different disease and environmental
insults in vitro and in vivo; however, I found that overexpression of mRBM3iso1 had no effect on
disease progression in the N171-82Q model. Consistent with these results, mRBM3iso1
overexpression did not rescue RTN3 levels, but curiously, also did not increase RTN3 levels in
WT mice. This indicated I might be missing an early dynamic increase in RTN3, or that
mRBM3iso1 and iso2 differentially regulate RTN3. I also wondered if the RBM3-RTN3 axis might
differ in the striatum, as experiments establishing that RBM3 directly increases RTN3 were
performed in murine hippocampus and HEK293 cells. I therefore overexpressed either isoform in
HD or WT striatum and collected tissue 4 weeks post-injection, versus 12 weeks post-injection in
my previous study. Overexpression of mRBM3iso1 or iso2 had no effect on RTN3 levels,
indicating that an early dynamic response or differences in RBM3 isoform do not account for my
findings. However, this result does point to the possibility that the RBM3-RTN3 axis differs
between cell types. I next induced cold stress in HEK293, Q7, and Q7/Q111 cells and, as
expected, measured significantly increased RBM3 levels in all cell lines. Surprisingly, cold stress
only increased RTN3 levels in the HEK293 cells, but not in the striatal-like cells, further
supporting my hypothesis that RBM3 differentially induces RTN3 depending on cell type.
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mHTT is ubiquitously expressed, but for reasons that are poorly understood prominently affects
MSNs. Although it is known that RBM3 mediates alternative polyadenylation, alternative splicing,
and microRNA biogenesis and many of RBM3’s RNA targets have been identified in nonneuronal cells, it is unclear which of these functions and RNA targets are critical in promoting
neuronal survival and synaptogenesis. RBM3 regulates pro-survival pathways through RNAdependent and RNA-independent mechanisms, and given that it binds over 5,000 RNA targets18,
likely alters many more pathways than we currently appreciate. It is possible that differential
regulation of these pathways renders MSNs more vulnerable to mHTT induced toxicity compared
to other neuronal cell types.

RBM3 and mTORC1
RBM3 and mTORC1 both increase global protein synthesis, RBM3 overexpression increases
p4EBP1, a downstream marker of mTORC1 activity, and enhancing mTORC1 is beneficial in HD
in vivo. I therefore originally hypothesized that RBM3 overexpression would be beneficial in HD
models by enhancing the mTORC1 pathway. In my long-term studies with mRBM3iso1 in N17182Q mice, I observed a significant increase in pAKT in the HD striatum, but no effects on the
downstream targets pmTOR or pS6. As pAKT activates mTOR through Rheb, and Rheb is
mislocalized in late stage N171-82Q heart4, these results suggest Rheb is also mislocalized in
HD brain, which we are currently investigating. While it was disappointing that mRBM3iso1
overexpression did not rescue HD phenotypes, these results support our previous findings that
mTORC1 is dysregulated in HD, and my hypothesis that RBM3 activates the mTORC1 pathway,
likely at or upstream of AKT.
Interestingly, while cold stress does not increase RTN3 in the striatal-like cells, it significantly
increases pmTOR and pS6 in Q7 and Q7/Q111 cells. This approach does not allow me to
distinguish between mRBM3iso1 and iso2 function, as both are presumably induced by cold
stress. I had previously found that mRBM3iso1 overexpression significantly enhances pAKT in
HD striatum and subtly enhances pAKT and pmTOR in WT striatum 12 weeks post-injection. I
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saw no effect on pS6 levels in either HD or WT striatum at this time point. To directly compare the
effects of mRBM3iso1 or iso2 on the mTORC1 pathway I performed short term overexpression
studies in the striatum of HD and WT mice. Unexpectedly, at 4 weeks post-injection, I found that
overexpression of mRBM3iso2 enhanced pAKT, pmTOR, and pS6 levels, and also increased
total mTOR and S6 compared to WT controls. In contrast, mRBM3iso1 overexpression had no
effect on the mTORC1 pathway 4 weeks post-injection, indicating mRBM3iso1 and mRBM3iso2
differentially affect mTORC1 activity. My finding that mRBM3iso1 overexpression robustly
induces pAKT 12 weeks post-injection but not 4 weeks post-injection, while mRBM3iso2
overexpression affects the entire pathway 4 weeks post-injection, raises many questions about
the inherent and dynamic function of these two isoforms.
The mTORC1 pathway has many regulatory feedback loops. In fact pS6K1, the intermediate
between mTORC1 and S6, negatively regulates the PI3K/AKT/mTORC1 axis19. Therefore,
inducers of mTORC1, provided they are not constitutively active, could cause an oscillating
pattern of mTORC1 activation, or their induction of mTORC1 may depend on other environmental
factors. Thus, caution is needed when assessing this pathway at a single time point. Studies with
additional time points utilizing both in vitro and in vivo models are needed to fully characterize the
dynamic effect of mRBM3iso1 and iso2 on the mTORC1 pathway.
The interaction between RBM3 and mTORC1 points to RBM3’s seemingly contradictory role in
both responding to cold stress, a state of reduced metabolism, and promoting global protein
synthesis. Further, why would cold stress induce mTORC1, a pathway that promotes growth and
metabolism?

One hypothesis is that RBM3 uniformly increases translation when induced,

therefore in the setting of hypothermia RBM3 induction prevents a severe reduction of protein
translation. Activation of the mTORC1 pathway by RBM3, then, may counteract the dramatic
effects of cold on metabolism thereby maintaining metabolic function above the level critical for
life. It is possible that the long-term effects of mRBM3iso1 and iso2 are ultimately redundant, but
that their localization allows for a more fine-tuned regulation of the cold stress response, which
may be more relevant in hibernating animals.
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As humans have only one RBM3 isoform, these differences may not seem applicable towards
treating disease. However, the mechanisms underlying hibernation may be key to solving a
number of health issues, providing insight into aging, obesity, resistance to blood loss, and even
maintaining muscle mass during space travel. The cytoprotective effect of cooling has been
demonstrated in numerous models12,20–22 and clinically-induced hypothermia is an effective
treatment for neonatal hypoxic-ischemic encephalopathy and adult acute brain injury23. Given the
risks associated with clinically-induced hypothermia, better understanding of basic RBM3 biology
towards developing an alternative form of induction is of interest. RBM3 is highly conserved,
however my data suggests that even small differences in RBM3 isoform can alter function.
Indeed, more work is required to determine which functions are shared between human RBM3
and the homologues I studied in vivo and in murine cell lines.
What is the mechanism behind RBM3 mediated mTORC1 activation? PAR-CLIP data from in
vitro overexpression studies indicates that RBM3 binds to over half of the genes involved in the
mTORC1 pathway, including PI3K, AKT, Rheb, mTOR, S6K1, and 4EBP118 (Fig 5.2). However,
RBM3 also targets several negative regulators of mTORC1, underlying the complexity of RBM3’s
post-transcriptional regulation of these targets. RBM3 could also regulate the mTORC1 pathway
through Wnt signaling, as RBM3 increases nuclear b-catenin levels, which inhibits the mTORC1
inhibitor GSK3 in vitro24. In addition to mediating various forms of post-transcriptional regulation,
RBM3 can also directly alter protein function and phosphorylation status22,25. This raises the
possibility that RBM3 also regulates the mTORC1 pathway through protein-protein interactions.
Moreover, as post-transcriptional regulation is tightly controlled in neurons it is essential to study
RBM3-RNA/protein interactions in specific neuronal and disease contexts.

In conclusion
RBM3 is implicated in the pathogenic cascade in multiple neurodegenerative diseases and is
emerging as a broadly protective protein in neuronal and nonneuronal settings. The RBM3 stress
response is deficient in other neurodegenerative disease models. In contrast, baseline and
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induced RBM3 expression, and protein stability, are dysregulated in HD. We have previously
shown that mTORC1 activity is reduced in HD human brain and in presymptomatic N171-82Q
mice3. My finding that cold stress and RBM3 enhance mTORC1 activity, but that RBM3 is
dysregulated in HD, indicates that deficits in RBM3 may contribute to reduced mTORC1 activity,
as summarized by Fig 5.3. Identifying the mechanisms behind RBM3 dysregulation is essential
towards translating RBM3 as a therapeutic target, as RBM3 may simply be reduced in some
disease settings, while its function may be impacted in others. For example, in AD, boosting
RBM3 levels may be a straightforward approach, while in HD, as long as mHTT is present at high
levels, RBM3 function will be hampered. Therefore, while mRBM3iso1 overexpression was not
beneficial in the N171-82Q HD model, boosting RBM3 levels in combination with mHTT
knockdown or other therapies should be investigated. Indeed, expressing RBM3 or RTN3 along
with modest levels mHTT knockdown may improve the therapeutic window of gene silencing
strategies for HD.
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Figure 5.1 Working model of the RBM3 stress response in HD and WT mice
RBM3 is repressed in the setting of Huntington’s Disease (HD), but is also activated by mHTT
mediated cellular stress, thereby leading to reduced or similar levels of RBM3 compared to WT.
The high level of cellular stress in the striatum of N171-82Q HD mice at 18 weeks leads to a
blunted induction of RBM3, resulting in RBM3 levels similar to WT baseline. At the same time
point, the cortex, which is less prominently affected than the striatum, is at a lower stress state
and therefore RBM3 levels are reduced compared to WT. Blue dotted line represents WT
baseline.
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Figure 5.2 RBM3 targets over half of the proteins involved in the mTOR signaling pathway
KEGG pathway analysis of RBM3 PAR-CLIP data reveals RBM3 binds the mRNA of many
proteins involved in the mTOR signaling pathway, including both inducers and repressors of this
pathway.
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Figure 5.3 Overarching hypothesis of RBM3 dysregulation in HD
Mutant huntingtin (mHTT) directly or indirectly represses RBM3 transcription, but RBM3 is also
induced in response to widespread cellular dysfunction in HD. In the setting of HD, RBM3
function is also dysregulated, possibly by direct interactions with mHTT or through aberrant
RBM3 protein modification. RBM3’s role in regulating the mTORC1 pathway, possibly through the
repression of GSK3 and activation of factors upstream of AKT, is disrupted, contributing to
reduced mTORC1 activity in HD. mHTT also interferes with downstream components of the
mTORC1 pathway, such as Rheb, indicating overexpressing RBM3 alone may not overcome
mHTT toxicity.
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CHAPTER 6

AAV-mediated progranulin delivery to a mouse model of progranulin deficiency causes T
cell-mediated toxicity
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Abstract
Adeno-associated virus-mediated gene replacement is emerging as a safe and effective means
of correcting single-gene mutations affecting the CNS. AAV-mediated progranulin gene (GRN)
delivery has been proposed as a treatment for GRN-deficient frontotemporal dementia and
neuronal ceroid lipofuscinosis, and recent studies using intraparenchymal AAV-Grn delivery to
brain have shown moderate success in histopathologic and behavioral rescue in mouse models.
Here, we used AAV9 to deliver GRN to the lateral ventricle to achieve widespread expression in
the Grn null mouse brain. We found that despite a global increase in progranulin, overexpression
resulted in dramatic and selective hippocampal toxicity and degeneration affecting neurons and
glia. Hippocampal degeneration was preceded by T cell infiltration and perivascular cuffing. GRN
delivery with an ependymal-targeting AAV for selective secretion of progranulin into the
cerebrospinal fluid similarly resulted in T cell infiltration as well as ependymal hypertrophy.
Interestingly, overexpression of GRN in wild-type animals also provoked T cell infiltration. These
results call into question the safety of GRN overexpression in the CNS, with evidence for both a
region-selective immune response and cellular proliferative response. Our results highlight the
importance of careful consideration of target gene biology and cellular response to
overexpression prior to progressing to the clinic.
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Introduction
Frontotemporal dementia (FTD)1, 2 and neuronal ceroid lipofuscinosis (NCL) type 11 (CLN11)3 are
neurodegenerative diseases resulting from haploinsufficiency or complete deficiency of
progranulin (GRN), encoded by the gene GRN. FTD symptoms range from behavioral changes to
language deterioration, with death ensuing in 3-5 years4. Nearly 70 FTD-causing GRN mutations
have been identified, accounting for up to 25% of inherited cases and >90% of which are
nonsense mutations1, 2, 5. For poorly understood reasons, GRN deficiency results in accumulation
of Tar-DNA binding protein of 43kD1,2 in characteristic inclusion bodies, with subsequent neuronal
loss and atrophy of frontal and temporal lobes. In CLN11, complete GRN deficiency leads to
lysosomal dysfunction and accumulation of lipofuscin, and a clinical syndrome of generalized
seizures, cognitive dysfunction, vision loss, and cerebellar degeneration6-8. Strategies to boost
GRN have been under development since its discovery as a major causal mutation for these
diseases9-11.

GRN is a secreted growth factor involved in development, wound healing, and immune
modulation12,

13

. In mice, Grn is expressed highly in neurons and is upregulated in activated

microglia following injury14. In human postmortem brain, GRN expression is widespread in both
normal and FTD subjects15. In vitro and in vivo, GRN plays a role in neuronal survival and neurite
outgrowth16-18, and a neuronal GRN receptor, sortilin, has been identified19. Based on its growth
promoting properties, GRN augmentation has been considered for treatment of a range of
neurodegenerative diseases. Indeed, lentivirus- and AAV-mediated GRN delivery to the central
nervous system (CNS) have been investigated in preclinical models of Alzheimer’s disease20, 21,
Parkinson’s disease22, motor neuron disease23, 24, and Huntington’s disease25.

Methods to augment GRN expression include enhancing transcription10 or translation9, increasing
extracellular GRN levels11, or using gene therapy. Among the latter, gene delivery using adenoassociated viral (AAV) vectors has risen to the forefront based on its excellent safety and efficacy
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profile and has been used in preclinical models of diverse diseases for several decades. Recent
successes in humans include treatment of hemophilia, Leber’s Congenital Amaurosis, and spinal
muscular atrophy26-28. To transduce the CNS, AAV can be delivered to brain parenchyma or
cerebrospinal fluid (CSF), with therapeutic benefit in preclinical models of both gain- and loss-offunction disease29-34. In contrast to peripheral administration35,36, numerous studies have shown
minimal innate or adaptive immune response to AAV-mediated gene delivery in the CNS.

A recent study using bilateral injection of AAV1.Grn- into the medial prefrontal cortex of Grn null
mice demonstrated focal improvements in lipofuscinosis, microgliosis, and lysosomal function37.
This group had previously used this approach in Grn haploinsufficient mice and showed
improvement in lysosomal readouts and social dominance deficits38. Notably, Grn null mice
displayed microglial activation at the injection site, with induction of anti-GRN antibodies37. No
other immunologic phenotypes were reported in this short-term study.

While these studies are promising, translation of intraparenchymal gene delivery to the human
brain is challenging. Our aim was to deliver GRN globally and sustainably using a method easily
translatable to humans, namely a single intraventricular injection of AAV.GRN. We selected AAV9
based on its ability to broadly disperse and infect neurons and glia after CSF delivery, as well as
its prior track record28,

34, 39

. We also tested AAV4 due to its ependymal selectivity and safety

profile30, 40, 41, to maximize CSF secretion with the goal of broad CNS uptake through the sortilin
receptor. Regardless of serotype, our studies show that over-expression of GRN in brain is
deleterious, causing profound neurodegeneration and raising concern about excessive
expression of GRN in mammalian brain as a therapy for FTD/NCL.

Results
Characterization of the Grn Null Phenotype
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As Grn haploinsufficient mice have minimal phenotypes, we used Grn null mice for our studies.
Mice lacking Grn have an age-dependent histopathologic phenotype consisting of habenular and
hippocampal vacuolation and increased ubiquitination starting at 7 months of age, as well as
diffusely increased astrogliosis and microgliosis starting at 12 months of age42-44. In our Grn null
animals, we confirmed the previously reported increase in vacuolation42, which was most
pronounced in the habenula and increased with age (figure 6.1A, arrowheads). Additionally, we
noted astrocytosis in the Grn null striatum that is present as early as 6 months and progresses
with age; this histopathological finding was not present even in 12-month-old WT mice (figure
6.1B) and has not been previously described. Hippocampal morphology was unaffected by
genotype at any age (figure 6.1C).

AAV-Mediated Gene Transfer Results in Sustained GRN Expression in Grn Null Mice
Grn null mice were injected with AAV9 encoding human GRN (AAV9.hGRN) (figure 6.2) into the
right posterior lateral ventricle at 6-7.5 months of age and sacrificed at time points ranging from 1
to 6 months post-injection. We observed the highest levels of GRN expression, as detected by
enzyme-linked immunoassay (ELISA), in the ipsilateral periventricular region; GRN levels
remained undiminished at 1-, 3-, 4.5- and 6 months post-injection compared to uninjected whole
brain tissue from null mice (figure 6.3A, left). We also observed high GRN levels in the ipsilateral
striatum and to a lesser extent, the ipsilateral frontal cortex, although cortical expression
diminished over time. Similarly high levels of GRN were detected in the contralateral
periventricular region (figure 6.3A, right), but with minimal increase in the left striatum or left
frontal cortex. GRN was additionally detected at moderate levels in the periventricular region of
the 3rd ventricle, the brainstem, and the spinal cord at all time points (data not shown). These
data indicate broad, sustained hGRN expression.

AAV9-Mediated Overexpression of GRN Causes Progressive Hippocampal Toxicity
Having established sustained expression of hGRN, we next performed detailed histological and
immunohistochemical analyses to assess for rescue in our treated mice. Grn null animals injected
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with AAV9.hGRN at 6-7.5 months of age and sacrificed 6 months after injection had striking
morphological and histological changes in the hemisphere ipsilateral to injection. Specifically, in
10 out of 10 injected animals, the hippocampus ipsilateral to the injection site showed a
hypercellular infiltrate often accompanied by loss of structural integrity (figure 6.4A). In all cases,
adjacent structures as well as the contralateral hippocampus appeared relatively unaffected.
Similar hippocampal degeneration occurred in Grn null mice injected with an AAV9 vector
delivering mouse Grn (figure 6.5), indicating that the response was not specific to delivery of a
human gene.

To better define the timeline of degenerative changes, animals were harvested soon after
injection. At one month post-injection with AAV9.hGRN, a hypercellular infiltrate was noted to
extend anteriorly and posteriorly along the entire hippocampus (figure 6.4B, left panels), most
prominent inferior to and within the hippocampal parenchyma. By 6 months post-injection,
prominent hypercellular infiltrates and perivascular cuffing accompanied loss of recognizable
hippocampal structures (figure 6.4B, right panels), and staining confirmed strong GRN
expression in these regions (figure 6.4C). Positive GRN staining was noted in neurons that
appeared to be healthy (figure 6.4C, lower inset) and in cells with pyknotic nuclei (figure 6.4C,
arrow). In contrast, littermate control animals treated with AAV9-delivered eGFP (AAV9.eGFP)
showed no pathology at 6 months post injection (figure 6.4D) and appeared similar to uninjected
littermates (data not shown), despite high levels of eGFP expression.

Indeed, over 4 timepoints after injection, in histopathological assessments performed by
observers blinded to treatment condition, 17/17 (100%) of AAV9.hGRN-injected animals showed
evidence of hippocampal toxicity, with 10/17 (59%) affected severely enough to cause atrophy
visible to the naked eye. In contrast, 0/18 (0%) of AAV9.eGFP-injected animals exhibited
evidence of toxicity (figure 6.4E).

Responses to hGRN Overexpression are Region and Cell-Type Specific
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Histological assessments were performed to determine if the hypercellular infiltrates and
degeneration observed after AAV9.hGRN delivery was present in other brain regions with high
levels of expression. No differences were seen between the cortex ipsilateral to the injection site
and either the contralateral cortex or that of AAV9.eGFP-injected controls at 6 months postinjection (figure 6.6A, B), despite moderately high GRN levels in cortical brain isolates (figure
6.3). Indeed, cortical neuron organization remained intact ipsilateral to the site of AAV9.hGRN
injection (figure 6.6C), and no obvious changes in architecture, neuronal number, or gliosis were
found in the ipsilateral striatum (figure 6.6D-G), an area with high GRN levels (figure 6.3). Brain
tissue from AAV9.eGFP-injected and uninjected animals was similar in appearance across all
parameters (data not shown). These results suggest that hGRN overexpression selectively
affects hippocampal brain regions.

To determine what cell types were affected in the hippocampus anteriorly (figure 6.7A-D) and
posteriorly (figure 6.7E-H), tissue sections were stained for the neuronal marker NeuN, the glial
marker GFAP, and the microglial marker Iba-1. In 13/17 (76%) of AAV9.hGRN-injected mice,
hippocampal neuronal loss was noted (figure 6.7B and 6.7F). Hippocampal astrocytes
demonstrated fewer, less robust processes (figure 6.7C and 6.7G), and microglial infiltration
ipsilateral to injection was prominent (figure 6.7D and 6.7H)45. In all cases, the side contralateral
to the injection (left panels) appeared similar to the hippocampus of both AAV9.eGFP-injected
and uninjected control littermates (data not shown). These data indicate that AAV9-mediated
hGRN overexpression is toxic to neurons and astrocytes in the hippocampus, and provokes a
strong local microglial response.

A T Cell Mediated Inflammatory Response Precedes Neuronal Loss and Occurs in Both
Wild-Type and Grn Null Animals
The hypercellular infiltrate found in AAV9.hGRN-injected animals consists of cells with a high
nucleus-to-cytoplasm ratio characteristic of lymphocytes. As such, sections were stained for the
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cell proliferation marker Ki-67, the B lymphocyte marker B220 (CD45), and the T lymphocyte
marker CD3.

As shown in figure 6.8, abundant proliferative cells were noted (figure 6.8B and 6.8F), and the
majority of these cells were positive for CD3 (figure 6.8C and 6.8G). In both anterior and
posterior sections, there was extensive perivascular cuffing by CD3+ cells both within and
adjacent to the hippocampus (figure 6.8G, arrowheads). These data collectively indicate a
robust T cell infiltration of the hippocampal region with minimal contribution from B cells.

To test if inflammatory infiltrates precede or follow the hippocampal degeneration, brain sections
from animals sacrificed at earlier time points after AAV9.hGRN injection were characterized. At
one month post-injection, hippocampal structures were maintained despite dense cellular
infiltration ventral to the hippocampus, with widespread perivascular cuffing lateral to and within
the hippocampus (figure 6.8I). Infiltrating cells were positive for CD3 and negative for B220,
indicating that T cell infiltration precedes hippocampal neurodegeneration.

In human autoimmune encephalitides, hippocampal degeneration often ensues from autoantibodies specific for hippocampal antigens. Triggering events may be expression of an ectopic
antigenic protein by a tumor or unmasking of a native hippocampal antigen by an inflammatory
process

46

. We thus tested whether hGRN overexpression elicited a similar pathophysiological

process in our Grn null animals using a previously-described rat hippocampal slice assay47. As
shown in figure 6.8J, serum from mice with the hippocampal degeneration phenotype screened
negative for anti-hippocampal antibodies, regardless of whether serum was drawn 1-, 3-, or 6
months after AAV9.hGRN injection. Moreover, AAV9.hGRN intraventricular delivery into wild-type
animals also elicited perivascular cuffing with infiltration of CD3 positive T cells as early as one
month after gene delivery, which became prominent and was accompanied by loss of
hippocampal structures by 3 months post-injection (figure 6.9). Taken together, these data
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support a role for T cell mediated hippocampal neurodegeneration following GRN
overexpression.

hGRN Delivered by the AAV4 Ependymal-targeting Vector Elicits an Inflammatory
Response and Ependymal Hypertrophy
AAV9 transduces multiple cell types, including neurons and glia48. We therefore asked whether
the observed inflammatory response and subsequent hippocampal degeneration was serotype
specific. For this we used AAV4, an ependymal-targeting serotype49 that allows secretion of
transgene products into the CSF30,

41, 50

. In Grn null mice injected at 6.5-8 months with

AAV4.hGRN in the right lateral ventricle, at the same dose as our AAV9.hGRN-injected animals,
GRN was detected throughout the brain by ELISA at mildly increased levels that were greatest in
ependyma-rich areas (data not shown). A hypercellular infiltrate was present throughout the
ventricular system as early as 1 month post-injection (figure 6.10A). This infiltrate was not
present in AAV4.eGFP-injected controls. Consistent with our previous findings, infiltrating cells
were positive for the T cell marker CD3 (figure 6.10A, right panels).

There was also marked ependymal and choroidal hypertrophy in the lateral ventricles adjacent to
the hippocampus (figure 6.10B, upper panel) as well as the 3rd ventricle (figure 610C, upper
panel), with corresponding T cell infiltration. By 3 months post-injection, the effect was so severe
as to have ablated the lateral ventricles (figure 6.10B, lower panel), with choroidal hypertrophy
nearly ablating the 3rd ventricle as well (figure 6.10C, lower panel). This effect was not seen in
AAV4.eGFP-injected mice at any time point (figure 6.10B and figure 6.10C), suggesting a direct
effect of GRN-induced cellular proliferation. Additionally, ependymal and choroidal hypertrophy
were not observed with AAV9-mediated gene delivery at any time (figure 6.10B and figure
6.10C). As AAV9 does not efficiently transduce ependymal cells, these data indicate a
hypertrophic effect on hGRN transduced ependymal cells. Of note, the hippocampus was
unaffected in AAV4.hGRN-treated mice, and GRN was not detected in this area (data not shown).
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To test if this is an effect of over-expression of transgenes, in animals null for a disease gene, we
subsequently examined brain sections from mucopolysaccharidosis type IIIA (MPS IIIA)
sulfamidase (SGSH) homozygous knockout mice treated with AAV4 expressing human SGSH, a
secreted protein, using the same dose, injection coordinates, and volume as our AAV4.hGRN
studies51. There was no observed toxicity in treated MPS IIIA mice (data not shown), supporting
an effect specific to GRN.

Cumulatively (Table 6.1), our data show that overexpression of progranulin in the brain can
trigger robust responses in the CNS that in turn, can cause cellular damage, irrespective of the
AAV serotype used for delivery.
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Tables
AAV9

1 month

3
months

6
months

9
months

AAV4

1 month

3
months

AAV9.
hGRN

3/3

2/2

10/10

2/2

AAV4.hGRN

3/3

3/3

AAV9.
eGFP

0/3

0/6

0/5

0/4

AAV4.eGFP

0/2

0/1

Table 6.1 Overview of studies performed in GRN null mice. Numerator represents number of
affected mice. Denominator represents number of treated mice at each time point.
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Figures

Figure 6.1. Grn null mice recapitulate previously published histopathologic findings and
exhibit previously undescribed abnormalities. A) Grn null mice exhibit vacuolation that is most
pronounced in the habenula and increases with age (arrowheads) and is absent from wildtype
mice at all time points. (Scale bars: 50 µm.) B) Grn null mice demonstrate an age-dependent
increase in astrocytosis compared to wildtype mice, as seen by GFAP staining. Shown here is the
striatum, an area in which astrocytosis in Grn null mice has not been previously described. (Scale
bars: 100 µm.) C) The hippocampus shows no gross morphological differences in Grn null mice
compared to WT at 6 or 12 months. (Scale bars: 250 µm.)
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Figure 6.2 Construct design and validation. A) Schematic of AAV transgene cassettes used in
our experiments. For AAV9 vectors, the CMV promoter was used to drive human progranulin
(hGRN), mouse progranulin (mGrn), or enhanced green fluorescent protein (eGFP), followed by
the bovine growth hormone polyA (bGHpA), and flanked by AAV2 inverted terminal repeats (ITR).
For AAV4 the CAG promoter was used to drive hGRN or eGFP, followed by the bovine growth
hormone polyA (bGHpA), flanked by the AAV2 inverted terminal repeats (ITR). B) Plasmid
expression was validated by transfection of HEK293 cells (QBI) with lipofectamine 2000 and
measuring hGRN or mGRN levels by ELISA in the media or lysate, 24 or 48 hours after
transfection as indicated. Our expression plasmids are compared to non-transfected cells (NTC),
cells transfected with the empty vector (5/TO) or eGFP transfected cells. C) Schematic of hGRN,
mGRN, and rat GRN (rGRN) protein consensus and alignments. rGRN and mGRN share 75.4%
and 75.2% identity to hGRN respectively.

90

Figure 6.3 AAV9 mediates sustained expression of GRN in Grn null mouse brain. Grn null
mice were injected at 6-7.5 months of age with AAV9.hGRN or AAV9.eGFP in the right lateral
ventricle and sacrificed 1, 3, 4.5, or 6 months post-injection. Brains were microdissected and
GRN levels measured by ELISA. (A, left) GRN levels in the right (injected) peri-ventricular area
(RV), right striatum (RStr), right frontal cortex (RFC) and uninjected homogenized whole brain
(WB) are shown. (A, right) GRN levels in the left (uninjected) peri-ventricular area (LV), left
striatum (LStr), left frontal cortex (LFC) and uninjected homogenized whole brain (WB) are
shown. (B) Schematic illustrating the regions collected by microdissection in blue (striatum), red
(cortex), and purple (peri-ventricular area). n=3 mice/group at each time point.
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Figure 6.4 Overexpression of GRN is toxic to cells of the hippocampus.
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Figure 6.4 Legend
Overexpression of GRN is toxic to cells of the hippocampus. Mice were injected at 6-7.5
months of age and sacrificed 1-6 months post-injection, and brains were either embedded and
stained for immunohistochemical analysis (A-D) or sectioned and imaged fluoroscopically (E). (A,
left) Histological differences were observed between the injected and uninjected hemispheres in
10 of 10 mice 6 months after injection of AAV9.hGRN, in 6 of whom there was grossly visible
atrophy of the hippocampus on the injected side. (A, right) H&E of AAV9.hGRN injected mouse
brain reveals marked degeneration of the hippocampus ipsilateral to injection and a dense
cellular infiltrate throughout the remaining hippocampal tissue, extending from anterior (upper
panel) to posterior (lower panel). B) The cellular infiltrate is observed along the length of the
hippocampus as early as 1 month post-injection of AAV9.hGRN, both inferior to (arrows) and
within the parenchyma of the hippocampus (left panels; n = 3 mice). By 6 months, histological
changes are observed in 10 of 10 mice, with 6 of 10 showing pervasive cell loss (right panels).
(Scale bars: 250 µm.) C) High levels of GRN are detected throughout the hippocampus at all time
points, with a diffuse cytoplasmic pattern of expression (inset). In some cases, cells expressing
GRN exhibit pyknotic nuclei (arrow). Shown here is GRN expression 6 months post injection.
(Scale bars: 50 µm; inset: 25 µm.) (D, left panels) AAV9.eGFP injected brains do not display cell
loss or hypercellular infiltrate at 1 (n=3), 3 (n=6), 6 (n=5) and 9 (n=4) months post-injection and
are similar in appearance to those of uninjected Grn null mice (n=4 age-matched littermates to 6
month cohort, data not shown). 6 months post injection shown. (Scale bars: 250 µm.) (D, right
panels) High levels of eGFP expression are detected by fluorescence microscopy adjacent to the
injection site, with cross-over to the contralateral side. Shown here is expression 3 months post
AAV9.eGFP injection. E) Quantitative assessment of hippocampal toxicity by raters blinded to
treatment condition showed toxicity ranging from hypercellular infiltrates to pervasive cell loss in
17/17 (100%) of AAV9.hGRN-treated animals, compared to 0/18 (0%) of AAV9.eGFP-treated
animals. Data are presented as mean +/- SEM.
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Figure 6.5 Gross morphological changes are observed in AAV9.hGRN- and AAV9.mGrninjected Grn null mice. Mice were injected with AAV9.hGRN, AAV9.mGrn, or AAV9.eGFP at 67.5 months of age and sacrificed 6 months post-injection. Brains were cut into 2mm sections prior
to microdissection. While uninjected (A) and AAV9.eGFP-injected (B) mice show no overt
morphological differences, the injected (right) hemisphere of mice treated with AAV9.hGRN (C)
and AAV9.mGrn (D) was noticeably smaller, specifically in the hippocampal region (arrows), with
surrounding regions appearing unaffected. n=10 mice treated with AAV9.hGRN (6 grossly
affected and remainder affected when assessed histologically), n = 3 mice treated with
AAV9.mGrn (3 grossly affected), n=4 mice treated with AAV9.eGFP (0 affected), n=4 mice
uninjected (0 affected).
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Figure 6.6 The cortex and striatum are unaffected by GRN overexpression. A) The ipsilateral
cortex immediately adjacent to the degenerated hippocampus appears unaffected by
AAV9.hGRN overexpression when compared to the contralateral cortex and to cortex ipsilateral
to AAV9.eGFP injected brain. Gross morphology, layer organization, and neuronal numbers
appear unremarkable by H&E staining (B; n=10 AAV9.hGRN-injected mice, n=5 AAV9.eGFPinjected mice assessed); NeuN staining confirms intact neuronal appearance (C). (Scale bars:
100 µm.) Similarly, the ipsilateral striatum directly anterior to the degenerated hippocampus (D)
appears unremarkable by H&E (E), NeuN (F), and GFAP (G) staining compared to AAV9.eGFP
injected controls 6 months post-injection (scale bars: 100 µm), as well as to uninjected controls
(data not shown).
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Figure 6.7 AAV9.hGRN-overexpressing mice undergo cell-specific hippocampal
degeneration. H&E-stained coronal sections show hippocampal degeneration 6 months postinjection on the injected side anteriorly (A) and posteriorly (E), with boxes indicating regions
magnified below (B-D, F-H). On the injected side, NeuN staining shows striking neuronal loss
throughout all regions of the hippocampus both anteriorly (B) and posteriorly (F); GFAP staining
shows qualitative loss of astrocytic processes in anterior (C) and posterior (G) hippocampus; Iba1 staining for microglia shows a dense microglial infiltrate in the hippocampal region anteriorly (D)
and posteriorly (H). Throughout the hippocampus there is a dense cellular infiltrate in the
ependymal space underlying the hippocampus (F-H) ipsilateral to injection. (Scale bars: 100 µm.)
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Figure 6.8 Hippocampal degeneration is characterized by a T cell inflammatory response
that precedes cell death.
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Figure 6.8 Legend
Hippocampal degeneration is characterized by a T cell inflammatory response that
precedes cell death. Mice were injected with AAV9.hGRN at 6-8 months of age and sacrificed 6
months post-injection (A-H) or 1 month post-injection (I). H&E-stained coronal sections show
hippocampal degeneration 6 months post-injection on the injected side anteriorly (A) and
posteriorly (E), with boxes indicating regions magnified below (B-D, F-H). On the injected side, Ki67 staining demonstrates proliferating cells throughout the hippocampus anteriorly (B) and
posteriorly (F); CD3 staining identifies most of these proliferating cells as T cells (C, G), while
B220 staining for B cells is largely negative (D, H), aside from some positively stained cells in the
dense posterior sub-hippocampal infiltrate (H). (Scale bars: 100 µm.) Mice were then examined
at 1 month post injection (I). H&E staining shows a dense infiltrate in the ependymal space
inferior to the hippocampus that is CD3+ and B220- (left box and magnifications below; scale
bars: 100 µm). In the CA2/3 region, there is also dense hypercellularity with perivascular cuffing
that is CD3+ and B220- (right box and magnifications on right; scale bars: 100 µm, n=3 mice
analyzed). (J) Rat brain slices were incubated with mouse serum from uninjected (first, n=3),
AAV9.eGFP-injected (second, n=2), or AAV9.hGRN-injected (third, n=5) mice at 6 months post
injection, with GAD65+ mouse serum used as a positive control for antibody-based hippocampal
reactivity (bottom). There was no immune reactivity in serum collected from mice injected with
AAV9.hGRN at 6 months, or at 1 (n=3) or 3 (n=2) months after AAV9.hGRN injection (data not
shown). (Scale bars: 250 µm.)

98

Figure 6.9 Wildtype mice also mount a T cell response accompanied by hippocampal
cellular loss after injection with AAV9.hGRN. Wildtype background-matched mice were
injected in the right lateral ventricle at 6 months of age with AAV9.hGRN and sacrificed at 1- (data
not shown) or 3 months post-injection (n=2 mice/time point). A hypercellular infiltrate was
observed most prominently adjacent to the third ventricle ipsilateral to injection (A) and extending
posteriorly throughout the hippocampus (B, C). The infiltrate extended inferior to the
hippocampus (arrows) as well as within the parenchyma, where we observed marked loss of cells
in the CA2/3 region of the hippocampus on the injected side compared to the uninjected side
(arrowheads; n=1/2 mice affected at 1 month and 2/2 mice at 3 months). There was no evidence
of cell loss or hypercellular infiltrate in AAV9.eGFP-injected WT mice (n=2 at 3 months, data not
shown).
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Figure 6.10 Grn null mice expressing GRN delivered by an ependymal-targeting vector
(AAV4) show an inflammatory response and ependymal hypertrophy.
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Figure 6.10 Legend
Grn null mice expressing GRN delivered by an ependymal-targeting vector (AAV4) show
an inflammatory response and ependymal hypertrophy. Mice were injected at 6.5-8 months
of age in the right lateral ventricle with AAV4.hGRN and sacrificed 1 or 3 months post-injection. At
one month, AAV4.hGRN-injected mice show a dense cellular infiltrate throughout the ependyma
underlying the hippocampus (A, middle panels) that is not present in uninjected age-matched
controls (A, left panels) or in AAV4.eGFP-injected littermates (data not shown). (Scale bars: 250
µm.) The infiltrate is highly positive for the T cell marker CD3 in all regions (A, right panels; scale
bars: 100 µm). When compared to age-matched AAV9.hGRN injected mice, AAV4.hGRNinjected mice show unique choroidal and ependymal hyperplasia and thickening and dense T cell
infiltration in the ipsilateral (B) and contralateral (data not shown) lateral ventricles that worsens
with time to the point of effacement by 3 months post-injection (scale bars: 100 µm). This is also
apparent in the 3rd ventricle, where the ependyma are thickened and the choroid nearly fills the
ventricle by 3 months, again with a T cell infiltrate (C; scale bars: 100 µm). 3/3 AAV4.hGRNinjected mice were affected at each of the 1 and 3 month post-injection time points, while
AAV4.eGFP control brains were not affected (n=2 at 1 month and 1 at 3 months).
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Figure 6.11 Hippocampal pathology for AAV9.hGRN or AAV9.eGFP-treated mice was
assessed using a rating scale. A score of 0 was given if no pathology was seen. A score of 1
indicated that a hypercellular infiltrate was present but there was no cell loss. A score of 2
indicated cellular loss but in a restricted area, whether anterior only, posterior only, or throughout
but affecting a small portion of the hippocampus. A score of 3 indicated pervasive cell loss
affecting a large portion of the hippocampus. Reviewers were first trained using this scale and
then presented with an anterior and a posterior image for each mouse. Each reviewer assigned a
score based on observed pathology and was blinded with regards to treatment or time postinjection.
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Discussion
In these studies we sought to test the safety and efficacy of AAV-mediated GRN expression in a
Grn null mouse model, towards development of a gene replacement strategy for treatment of
GRN-deficient FTD and CLN11. To our surprise we found that AAV9-mediated GRN or Grn
overexpression led to hippocampal toxicity in 100% of Grn null mice, with hippocampal
neurodegeneration in nearly all, while AAV9-mediated eGFP overexpression had no deleterious
effect. The observed degeneration was markedly selective, with sparing of the cortex above,
striatum anterior to, and thalamic structures inferior to the hippocampus, despite high GRN levels
in these tissues. We also observed a cellular infiltrate primarily composed of T cells as well as
perivascular cuffing preceding the onset of hippocampal degeneration and persisting until late
stages of degeneration. In addition, we detected a T cell mediated immune response irrespective
of the genetic background of the mouse injected, and irrespective of the AAV serotype used, as
well as a direct hypertrophic effect of GRN following AAV4 delivery to ependyma cells. The
consistent observation of toxicity in GRN injected mice in multiple experimental settings, and no
evidence of toxicity in any of the eGFP injected control mice, strongly points to GRN
overexpression as the direct cause. These data emphasize the need for caution in pursuing GRN
delivery in the human CNS.

Toxicity in our study was region-selective, with hippocampal neurodegeneration preceded by T
cell infiltration in the case of AAV9-mediated GRN delivery, and severe damage to the ventricular
system via ependymal hypertrophy and T cell infiltration when GRN was expressed following
AAV4 transduction of ependyma. We considered various explanations for our findings, starting
with serotype. The tropism of AAV9 for neurons and glia, and of AAV4 for ependymal cells, might
have resulted in toxic levels of transgene expression in their target tissues. However, in contrast
to GRN, eGFP delivered by either AAV9 or AAV4 vectors did not elicit a degenerative or
inflammatory response. This suggests that the choice of serotype and high levels of transgene
expression alone are not sufficient to explain our findings. This is supported by many others’
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works in which overexpression by these serotypes in a variety of null or haploinsufficient models
have not led to robust immune responses.

Second, the intraventricular delivery route chosen here may have triggered immunogenicity and
downstream tissue destruction. In this respect, the recent reports by Arrant et al. demonstrating
rescue in mouse models of FTD and CLN11 after intraparenchymal delivery of Grn are
noteworthy37, 38; GRN was expressed in mice lacking one or both copies of Grn but there was not
dramatic hippocampal degeneration or ependymal toxicity. It is possible that the intraventricular
route exposes particular antigen-presenting cells to GRN, thus provoking the T cell infiltration and
inflammation observed in our animals. Our strategy was based on considerations of eventual
clinical translation for GRN-deficient human diseases, for which intraparenchymal delivery poses
safety and feasibility issues in humans. Moreover, intraventricular CNS delivery of many
transgenes has been successfully achieved in preclinical models, including in animals null for the
therapeutic gene.

In mice, at doses and injection routes similar to ours, gene replacement

strategies have consistently been safely achieved in null models; for instance, one group safely
delivered the ATP-binding cassette transporter (ABCD1) gene in a mouse model of X-linked
adrenoleukodystrophy39. Similarly, in our studies, overexpression of eGFP, a completely foreign
protein, was well tolerated irrespective of serotype. Furthermore, MPS IIIA SGSH-null mice
treated with AAV4.SGSH, a secreted protein, using the same approach as our study, showed no
sign of hippocampal or ventricular degeneration, or of cellular infiltrate51. Cumulatively the data
suggest that our results are specific to overexpression of GRN as a target gene, rather than route
of delivery, dose, expression of a human gene in a null mouse model, or expression of a secreted
protein.

While much of the literature in the >10 years since GRN mutations were first linked to
neurodegeneration concerns the role of GRN as a neurotrophic factor14, 16-18, GRN is also widely
expressed in cell types ranging from epithelial cells to hematopoietic cells, macrophages, and T
cells12, 13. Early studies described its role in wound healing and regulation of inflammation, which
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while poorly understood involves an interplay between GRN, which is itself active, and its
cleavage products, the granulins, which have opposing effects on a number of immune cellmediated processes13. Thus, the existing literature on GRN suggests that tight regulation of its
expression, both on the transcriptional side and with respect to the protein cleavage events that
generate daughter peptides, may be needed to avoid untoward immunological effects.

There is also extensive literature on involvement of GRN in cell growth and proliferation, both in
normal development and in cancer12, 13. Indeed, GRN is overexpressed and promotes cell growth
in many tumors, including glioblastoma52,
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. In this respect, our findings using AAV4-mediated

hGRN delivery are noteworthy. In mice, AAV4 selectively targets ependymal cells and
subventricular astrocytes54 and AAV4-mediated hGRN delivery resulted in marked hypertrophy of
the ependyma, suggesting a direct effect of GRN on the targeted cells accompanied by T cell
infiltration.

Arrant et al., recently reported reversal of phenotypes associated with GRN deficiency using AAV
mediated replacement therapy in Grn null mice, with no reported evidence of T cell infiltration or
hippocampal degeneration. Despite differences in our approach (intraventricular versus
intraparenchymal), vector (AAV9 or AAV4 versus AAV1), dose (higher in our study), and
transgene (our vector does not have a Myc tag and can interact with sortilin), both we and Arrant
et al. observe an immune response. In the case of Arrant et al., the response consists of profound
microglial activation and MHCII presentation at the injection site, as well as antibodies to GRN
detected in plasma. In our studies, by contrast, we observed T cell infiltration and destruction of
neurons and astrocytes in the hippocampus. It is possible that, given a longer period of time,
evidence of neuronal degeneration or unchecked growth would emerge in their studies. Indeed,
Arrant et al. remarked that the upregulation of MHCII is typically associated with a T cell response
and speculated that a longer exposure could result in T cell mediated neuronal degeneration and
functional deficits.
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These findings raise concerns regarding how to safely translate these studies into humans.
Specifically, our combined data suggest that GRN replacement could be highly immunogenic in
CLN11 (GRN null) patients. For FTD due to haploinsufficiency, high levels of GRN may be
required to reverse disease, which in turn, may induce either tumorigenic growth effects of GRN
or an immune response to transduced cells. To tease apart whether toxicity is dependent on the
growth-promoting properties of GRN, overexpression in target cells, or host naiveté, additional
studies are needed in heterozygous models with progranulin variants. As a final consideration,
future pharmacological toxicity studies of the wild type human protein may remain a challenge, as
overexpression will be problematic in rodents.

In summary, while GRN-associated FTD and NCL are attractive targets for gene replacement
therapy, our results suggest that concerns stemming from the identity and function of the
transgene – GRN – are paramount in considerations of a path to human intervention.
Specifically, work elucidating the mechanisms by which GRN modulates inflammatory and growth
responses, particularly in the CNS, are needed. Our work highlights the potential for inflammatory
and tumorigenic effects of GRN overexpression, to which specific attention should be paid in
preclinical models. More broadly, these findings call into question our current conception of the
brain as an immune privileged organ broadly tolerant of transgene over-expression.
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Materials and Methods
Viral Vector Constructs
AAV serotype 9 and AAV serotype 4 were used for these studies. AAV9 vectors contained a
cytomegalovirus (CMV) promoter, while AAV4 vectors contained a chicken ß actin (CBA)
promoter. The human GRN cDNA (GenBank accession no. BC000324) was amplified from a
Hek293 cell cDNA library and the mouse Grn cDNA (GenBank accession no. NM_008175) was
cloned using gBlocks (IDT). The transgenes or an eGFP reporter gene were inserted into the
G0347 pFB.AAV.CMV.bHGpA plasmid (Iowa Vector Core, Iowa City, IA) and were then used to
produce AAV vectors by the Children’s Hospital of Philadelphia (CHOP) Research Vector Core
(Philadelphia, PA). All constructs were verified by Sanger Sequencing (CHOP Napcore,
Philadelphia, PA).

Mice
Generation of progranulin-null (Grn null) mice on a C57BL/6J background through targeted
disruption of the Grn gene has been reported previously55. Grn null mice were provided to the
University of Pennsylvania from the Nishihara laboratory at the University of Tokyo, and the
colony was expanded and maintained. Male and female wildtype C57BL/6J (WT; Jackson labs,
Bar Harbor, ME) and Grn null mice ages 6-15 months were used in these studies, as well as agematched wildtype C57BL/6J controls. Mice were housed in a controlled temperature environment
on a 12-hour light/dark cycle and were given free access to food and water. All animal studies
were approved by the Institutional Animal Care and Use Committee of the University of
Pennsylvania. MPS IIIA Sgsh null and heterozygous mice were generated and maintained as
previously described51 and studies approved by the Institutional Animal Care and Use Committee
of the Children’s Hospital of Philadelphia.

Stereotaxic Delivery
Mice were deeply anaesthetized with isoflurane and immobilized in a stereotaxic frame (David
Kopf instruments, Tujunga, CA) installed with both a digital stereotaxic control panel (Leica
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Biosystems, Buffalo Grove, IL) and microinjection robot (KD Scientific, Holliston, MA) for
motorized injections. Mice were injected unilaterally by a team of the same two operators in the
posterior right lateral ventricle via a Hamilton syringe using the following coordinates: AP, -2.18
mm; ML, -2.9 mm; and DV, -3.5 mm (from bone) relative to bregma. Each mouse received 10 µL
of vector at a concentration of 5e+12 vg/ml for a total dose of 5e+10 VG, with the exception of
AAV4.eGFP which was delivered at a concentration of 4e+11 vg/ml for a total dose of 4e+9 VG.
Vectors were infused at a rate of 0.5 µL/min with a 3 minute wait time post-infusion prior to
withdrawal of the trochanter. All vector dilutions were prepared in parallel using the same diluent,
and experimental and control mice were injected on the same day in a mixed order. Mice were
injected between 6-8 months of age and euthanized between 1 and 9 months post-injection. MPS
IIIA Sgsh null and heterozygous mice were injected at 2 months and euthanized at 5.5 months as
previously described51.

Mouse Brain Isolation
Mice were sacrificed at indicated ages by anesthetizing with a ketamine/xylazine/acepromazine
mixture, followed by transcardial perfusion with 15mL of ice-cold 0.9% phosphate-buffered saline
(PBS). Brains were quickly removed from the skull. Those used for fluorescent imaging studies
were fixed whole in 4% paraformaldehyde overnight at 4oC followed by placement in a 30%
sucrose/0.05%

sodium

azide

solution

for

cryoprotection

at

4oC.

Those

used

for

immunohistochemistry or for GRN quantification by ELISA were blocked into 2mm-thick coronal
slices and then either fixed in 4% paraformaldehyde overnight at 4oC or microdissected and flashfrozen in liquid nitrogen, respectively.

Protein Extraction
Frozen isolated brain tissues were weighed and transferred to a 500 µL Potter-Elvehjem dounce
homogenizer

(Sigma-Aldrich,

Allentown,

PA),

and

manually

homogenized

in

1%

radioimmunoprecipitation buffer (RIPA; 50 mM Tris, 150 mM NaCl, 5mM EDTA, 0.5% sodium
deoxycholate, 1% NP-40, 0.1% sodium dodecyl sulfate [SDS], pH 8.0) with 0.2% phenylmethane
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sulfonyl fluoride (PMSF) and 0.1% protease inhibitors (Penn Center for Neurodegenerative
Research [CNDR], Philadelphia, PA). Homogenates were centrifuged at 21,380 RCF for 30
minutes and supernatant harvested, and protein concentration was measured by Pierce
colorimetric BCA protein assay (ThermoFisher Scientific, Waltham, MA). GRN was quantified by
human progranulin ELISA kit (Adipogen, San Diego, CA). 118 µg of total protein was plated per
well, with samples run in duplicate. Plates were read on a Berthold LB941 TriStar vTI Multimode
reader (Berthold Technologies, Bad Wildbad, Germany) at a wavelength of 450 nm and
progranulin concentration calculated using the provided standard curve per kit instructions.

Antibodies
Primary antibodies used for immunohistochemistry included the following: anti-human GRN (antihGRN) rabbit polyclonal antibody (0.01 mg/mL; developed by CNDR, Philadelphia, PA as
previously described15), anti-NeuN rabbit polyclonal antibody (0.5 µg/mL; ABN78; Sigma-Aldrich,
St. Louis, MO), anti-GFAP rabbit polyclonal antibody (0.58 µg/mL; Z0334; Dako/Agilent, Santa
Clara, CA), anti-Iba1 rabbit polyclonal antibody (0.25 µg/mL; Saf5299; Wako, Richmond, VA),
anti-Ki67 rabbit monoclonal antibody (dilution 1:1000; Ab16667; Abcam, Cambridge, UK), antiCD45R rat monoclonal antibody (5 µg/mL; RA3-6B2; Invitrogen, Carlsbad, CA), and anti-CD3e
rabbit monoclonal antibody (dilution 1:150; MA1-90582; Invitrogen, Carlsbad, CA). Biotinylated
goat anti-rabbit and goat anti-rat IgG secondary antibodies (Vector laboratories, Burlingame, CA)
were used at a concentration of 1.5 µg/mL in all cases except for anti-hGRN, for which secondary
antibody concentration was 7.5 µg/mL. In the autoantibody studies, biotinylated goat anti-mouse
IgG secondary antibody (Vector laboratories, Burlingame, CA) was used at a concentration of
0.75 µg/mL.
Section preparation and immunohistochemistry
Fixed coronal brain slices were serially ethanol-dehydrated and paraffin-embedded. Blocks were
sectioned coronally at 6 µm and incubated at 37-42oC overnight. Sections were deparaffinized in
Xylene and rehydrated in serially dilute ethanol solutions, and were either stained with
hematoxylin (ThermoScientific, Kalamazoo, MI) and eosin (Fisher Chemical, Waltham, MA)
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(H&E) or underwent immunohistochemical (IHC) staining, as follows: sections underwent
deactivation of endogenous peroxidase with 5% hydrogen peroxide in methanol for 30 minutes as
well as microwave antigen retrieval using antigen unmasking solution (Vector laboratories,
Burlingame, CA), followed by washing in Tris buffer then blocking against nonspecific binding
sites with 2% fetal bovine serum for 30 minutes at room temperature. Sections were then
incubated in primary antibody overnight at 4oC in humidified chambers, blocked again, and
incubated in biotinylated secondary antibody for one hour at room temperature. Sections were
again blocked, followed by treatment for one hour with the VECTASTAIN ABC kit (Vector
laboratories, Burlingame, CA) for avidin binding and peroxidation, then treated with Vector
ImmPACT 3,3′-Diaminobenzidine (DAB) peroxidase substrate solution for detection (Vector
laboratories, Burlingame, CA). Sections were counter-stained with hematoxylin and dehydrated
prior to coverslipping. Brightfield images were taken on a Nikon 80i upright fluorescence
microscope and analyzed with Nikon NIS-Elements AR Imaging software.

Quantitation of hippocampal toxicity
A four-point scoring system was developed for rating degree of hippocampal toxicity, with 0
representing normal hippocampus, 1 representing presence of infiltrate without cell loss, 2
representing focal cell loss, and 3 representing pervasive cell loss (figure 6.11). Five evaluators
experienced in mouse brain histopathology were presented with an anterior and a posterior H&Estained slide from each mouse, blinded with regards to time point and treatment. Each evaluator
independently assigned each animal a score from 0-4, using the scale described as a reference,
and an average score was computed for each mouse. These scores were then averaged for each
treatment group at each time point and plotted along with standard error of the mean.

Section preparation and fluorescence imaging
Fixed, cryoprotected brains were sectioned at 60 μm on a freezing microtome and stored at -20oC
in a cryoprotectant solution (30% ethylene glycol, 15% sucrose, 0.05% sodium azide in
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phosphate buffered saline) until use. Sections were imaged using a DM6000B Leica microscope
equipped with a Hamamatsu ORCA-Flash4.0 camera.

Autoantibody detection
Studies were performed as previously described
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. Adult female Wistar rats were anesthetized

and decapitated. Brains were removed and washed in 1x phosphate-buffered saline (PBS), then
bisected sagitally and fixed in 4% paraformaldehyde in PBS at 4oC for one hour. Brains were then
transferred to 40% sucrose in 0.1M PBS for 48 hours, followed by embedding in Tissue-Tek OCT
compound embedding medium (Sakura Finitek, Torrance, CA), then snap-frozen in 2methylbutane cooled with liquid nitrogen. Sections were cut sagitally at 7 µm, mounted on glass
slides, and stored at -20oC until use. Endogenous peroxidase was quenched with 0.3% hydrogen
peroxide in PBS for 15 minutes. Sections were blocked in 5% goat normal serum for one hour,
after which serum samples were applied to sections at a dilution of 1:200 in 5% normal goat
serum (Jackson ImmunoResearch Laboratories, West Grove, PA) and incubated overnight at 4oC
in humidified chambers. Sections were incubated in biotinylated goat anti-mouse secondary
antibody for 2 hours at room temperature, then treated for one hour with the VECTASTAIN Elite
ABC kit (Vector laboratories, Burlingame, CA) for avidin binding and peroxidation. Slides were
incubated for 30 seconds in 0.5% Triton X solution in PBS, then treated with Vector ImmPACT
DAB peroxidase substrate kit (Vector laboratories, Burlingame, CA) for detection. Slides were
counter-stained with 50% hematoxylin and dehydrated prior to coverslipping. Brightfield images
were taken on a Nikon 80i upright fluorescence microscope and analyzed with Nikon NISElements AR Imaging software.
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